



## Clinical trial results:

### A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

#### Summary

|                          |                               |
|--------------------------|-------------------------------|
| EudraCT number           | 2013-000685-11                |
| Trial protocol           | SE DE AT GB DK IT HU ES BE PL |
| Global end of trial date | 26 December 2021              |

#### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1              |
| This version publication date  | 01 January 2023 |
| First version publication date | 01 January 2023 |

#### Trial information

##### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 213356 |
|-----------------------|--------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |                                                                      |
|------------------------------|----------------------------------------------------------------------|
| Sponsor organisation name    | GSK                                                                  |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS   |
| Public contact               | GSK Response Center, GSK, 1 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | GSK Response Center, GSK, 1 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 12 December 2022 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 26 December 2021 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in participants who have platinum sensitive ovarian cancer as assessed by the prolongation of progression-free survival (PFS)

Protection of trial subjects:

Protocol Amendment 7 introduced less visits burden to participants, as so called "Extended Cycle Visit":

- Required in-clinic visit every cycle (28 days) optional; participants may visit the clinic every three cycles (84 days).
  - Option for in-home nursing visit or site local clinic/hospital except for visit every three cycles which must be performed at the site
  - Study assessments which can be performed by study coordinator through telephone contact include Adverse event, ConMed and Eastern Cooperative Oncology Group.
  - Study assessments which can be performed at the in home nursing visits, local clinic or hospital include vitals, blood draw (complete blood count, chemistry, CA-125) and dispensation of study drug
- Protective measures were also taken temporarily during Coronavirus disease-19 pandemic 2020/2021 by allowing most assessments done remotely, or locally; and providing study drug supply by courier to participants.

Background therapy: -

Evidence for comparator: -

|                                                           |              |
|-----------------------------------------------------------|--------------|
| Actual start date of recruitment                          | 21 June 2013 |
| Long term follow-up planned                               | No           |
| Independent data monitoring committee (IDMC) involvement? | Yes          |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 198 |
| Country: Number of subjects enrolled | Austria: 6         |
| Country: Number of subjects enrolled | Belgium: 18        |
| Country: Number of subjects enrolled | Canada: 66         |
| Country: Number of subjects enrolled | Germany: 52        |
| Country: Number of subjects enrolled | Denmark: 48        |
| Country: Number of subjects enrolled | Spain: 48          |
| Country: Number of subjects enrolled | France: 47         |
| Country: Number of subjects enrolled | United Kingdom: 32 |
| Country: Number of subjects enrolled | Hungary: 3         |
| Country: Number of subjects enrolled | Israel: 18         |
| Country: Number of subjects enrolled | Italy: 19          |
| Country: Number of subjects enrolled | Norway: 12         |

|                                      |            |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Poland: 15 |
| Country: Number of subjects enrolled | Sweden: 14 |
| Worldwide total number of subjects   | 596        |
| EEA total number of subjects         | 282        |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|-------------------------------------------|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 384 |
| From 65 to 84 years                       | 212 |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

This was a randomized, double-blind study conducted to analyze maintenance with niraparib versus placebo in participants with ovarian cancer.

### Pre-assignment

Screening details:

A total of 596 participants were enrolled in the study.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator          |

### Arms

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |                 |
|------------------|-----------------|
| <b>Arm title</b> | gBRCA Niraparib |
|------------------|-----------------|

Arm description:

Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Niraparib    |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Capsule      |
| Routes of administration               | Oral use     |

Dosage and administration details:

Participants received 3x100 milligrams of niraparib as oral dose.

|                  |               |
|------------------|---------------|
| <b>Arm title</b> | gBRCA Placebo |
|------------------|---------------|

Arm description:

Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.

|                                        |          |
|----------------------------------------|----------|
| Arm type                               | Placebo  |
| Investigational medicinal product name | Placebo  |
| Investigational medicinal product code |          |
| Other name                             |          |
| Pharmaceutical forms                   | Capsule  |
| Routes of administration               | Oral use |

Dosage and administration details:

Participants received placebo matching 3x capsules as oral dose.

|                  |                     |
|------------------|---------------------|
| <b>Arm title</b> | Non-gBRCA Niraparib |
|------------------|---------------------|

Arm description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                                                                                                                                                                                                                                                                                                                            |                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Investigational medicinal product name                                                                                                                                                                                                                                                                                                     | Niraparib                |
| Investigational medicinal product code                                                                                                                                                                                                                                                                                                     |                          |
| Other name                                                                                                                                                                                                                                                                                                                                 |                          |
| Pharmaceutical forms                                                                                                                                                                                                                                                                                                                       | Capsule                  |
| Routes of administration                                                                                                                                                                                                                                                                                                                   | Oral use                 |
| Dosage and administration details:                                                                                                                                                                                                                                                                                                         |                          |
| Participants received 3x100 milligrams of niraparib as oral dose.                                                                                                                                                                                                                                                                          |                          |
| <b>Arm title</b>                                                                                                                                                                                                                                                                                                                           | Non-gBRCA Placebo        |
| Arm description:                                                                                                                                                                                                                                                                                                                           |                          |
| Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression                                                                                                                                                                                                         |                          |
| Arm type                                                                                                                                                                                                                                                                                                                                   | Placebo                  |
| Investigational medicinal product name                                                                                                                                                                                                                                                                                                     | Placebo                  |
| Investigational medicinal product code                                                                                                                                                                                                                                                                                                     |                          |
| Other name                                                                                                                                                                                                                                                                                                                                 |                          |
| Pharmaceutical forms                                                                                                                                                                                                                                                                                                                       | Capsule                  |
| Routes of administration                                                                                                                                                                                                                                                                                                                   | Oral use                 |
| Dosage and administration details:                                                                                                                                                                                                                                                                                                         |                          |
| Participants received placebo matching 3x capsules as oral dose.                                                                                                                                                                                                                                                                           |                          |
| <b>Arm title</b>                                                                                                                                                                                                                                                                                                                           | FE sub-study: Fasted/fed |
| Arm description:                                                                                                                                                                                                                                                                                                                           |                          |
| Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods. |                          |
| Arm type                                                                                                                                                                                                                                                                                                                                   | Experimental             |
| Investigational medicinal product name                                                                                                                                                                                                                                                                                                     | Niraparib                |
| Investigational medicinal product code                                                                                                                                                                                                                                                                                                     |                          |
| Other name                                                                                                                                                                                                                                                                                                                                 |                          |
| Pharmaceutical forms                                                                                                                                                                                                                                                                                                                       | Capsule                  |
| Routes of administration                                                                                                                                                                                                                                                                                                                   | Oral use                 |
| Dosage and administration details:                                                                                                                                                                                                                                                                                                         |                          |
| Participants received 3x100 milligrams of niraparib as oral dose.                                                                                                                                                                                                                                                                          |                          |
| <b>Arm title</b>                                                                                                                                                                                                                                                                                                                           | FE sub-study: Fed/fasted |
| Arm description:                                                                                                                                                                                                                                                                                                                           |                          |
| Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.                               |                          |
| Arm type                                                                                                                                                                                                                                                                                                                                   | Experimental             |
| Investigational medicinal product name                                                                                                                                                                                                                                                                                                     | Niraparib                |
| Investigational medicinal product code                                                                                                                                                                                                                                                                                                     |                          |
| Other name                                                                                                                                                                                                                                                                                                                                 |                          |
| Pharmaceutical forms                                                                                                                                                                                                                                                                                                                       | Capsule                  |
| Routes of administration                                                                                                                                                                                                                                                                                                                   | Oral use                 |
| Dosage and administration details:                                                                                                                                                                                                                                                                                                         |                          |
| Participants received 3x100 milligrams of niraparib as oral dose.                                                                                                                                                                                                                                                                          |                          |
| <b>Arm title</b>                                                                                                                                                                                                                                                                                                                           | QTc sub-study: Niraparib |
| Arm description:                                                                                                                                                                                                                                                                                                                           |                          |
| Participants received Niraparib 300 mg once daily orally.                                                                                                                                                                                                                                                                                  |                          |
| Arm type                                                                                                                                                                                                                                                                                                                                   | Experimental             |

|                                        |           |
|----------------------------------------|-----------|
| Investigational medicinal product name | Niraparib |
| Investigational medicinal product code |           |
| Other name                             |           |
| Pharmaceutical forms                   | Capsule   |
| Routes of administration               | Oral use  |

Dosage and administration details:

Participants received 3x100 milligrams of niraparib as oral dose.

| <b>Number of subjects in period 1<sup>[1]</sup></b> | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib |
|-----------------------------------------------------|-----------------|---------------|---------------------|
| Started                                             | 138             | 65            | 234                 |
| Completed                                           | 0               | 0             | 0                   |
| Not completed                                       | 138             | 65            | 234                 |
| Consent withdrawn by subject                        | 20              | 11            | 29                  |
| Disease progression                                 | -               | -             | -                   |
| Adverse event, non-fatal                            | -               | -             | -                   |
| Death                                               | 72              | 29            | 146                 |
| Transferred to other arm/group                      | -               | -             | -                   |
| Subject unblinded by sponsor                        | 12              | 12            | 15                  |
| Other reasons                                       | 5               | 3             | 8                   |
| Lost to follow-up                                   | 7               | 2             | 5                   |
| Ongoing at the time of analysis                     | 22              | 8             | 31                  |

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Non-gBRCA Placebo | FE sub-study: Fasted/fed | FE sub-study: Fed/fasted |
|-----------------------------------------------------|-------------------|--------------------------|--------------------------|
| Started                                             | 116               | 8                        | 9                        |
| Completed                                           | 0                 | 7                        | 8                        |
| Not completed                                       | 116               | 1                        | 1                        |
| Consent withdrawn by subject                        | 14                | -                        | -                        |
| Disease progression                                 | 2                 | -                        | -                        |
| Adverse event, non-fatal                            | -                 | -                        | 1                        |
| Death                                               | 68                | -                        | -                        |
| Transferred to other arm/group                      | -                 | 1                        | -                        |
| Subject unblinded by sponsor                        | 14                | -                        | -                        |
| Other reasons                                       | 4                 | -                        | -                        |
| Lost to follow-up                                   | 1                 | -                        | -                        |
| Ongoing at the time of analysis                     | 13                | -                        | -                        |

| <b>Number of subjects in period 1<sup>[1]</sup></b> | QTc sub-study: Niraparib |
|-----------------------------------------------------|--------------------------|
| Started                                             | 26                       |

|                                 |    |
|---------------------------------|----|
| Completed                       | 0  |
| Not completed                   | 26 |
| Consent withdrawn by subject    | 4  |
| Disease progression             | -  |
| Adverse event, non-fatal        | -  |
| Death                           | 5  |
| Transferred to other arm/group  | -  |
| Subject unblinded by sponsor    | -  |
| Other reasons                   | 17 |
| Lost to follow-up               | -  |
| Ongoing at the time of analysis | -  |

---

Notes:

[1] - The number of subjects transferring in and out of the arms in the period are not the same. It is expected the net number of transfers in and out of the arms in a period, will be zero.

Justification: Subject is transferred to another treatment group

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                                                                                                                                                            |                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | gBRCA Niraparib          |
| Reporting group description:<br>Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.                                                                                                                                                                  |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | gBRCA Placebo            |
| Reporting group description:<br>Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.                                                                                                                                                                                           |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | Non-gBRCA Niraparib      |
| Reporting group description:<br>Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.                                                                                                                                                                                           |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | Non-gBRCA Placebo        |
| Reporting group description:<br>Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression                                                                                                                                                                                                         |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | FE sub-study: Fasted/fed |
| Reporting group description:<br>Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods. |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | FE sub-study: Fed/fasted |
| Reporting group description:<br>Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.                               |                          |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | QTc sub-study: Niraparib |
| Reporting group description:<br>Participants received Niraparib 300 mg once daily orally.                                                                                                                                                                                                                                                                                  |                          |

| Reporting group values                        | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib |
|-----------------------------------------------|-----------------|---------------|---------------------|
| Number of subjects                            | 138             | 65            | 234                 |
| Age Categorical<br>Units: Participants        |                 |               |                     |
| <=18 years                                    | 0               | 0             | 0                   |
| Between 18 and 64 years                       | 110             | 49            | 130                 |
| >=65 years                                    | 28              | 16            | 104                 |
| Sex: Female, Male<br>Units: Participants      |                 |               |                     |
| Female                                        | 138             | 65            | 234                 |
| Male                                          | 0               | 0             | 0                   |
| Race/Ethnicity, Customized<br>Units: Subjects |                 |               |                     |
| American Indian or Alaska Native              | 1               | 0             | 0                   |
| Asian                                         | 2               | 3             | 10                  |
| Native Hawaiian or Other Pacific Islander     | 0               | 0             | 0                   |
| Black or African American                     | 1               | 1             | 4                   |

|                         |     |    |     |
|-------------------------|-----|----|-----|
| White                   | 123 | 55 | 201 |
| Unknown or Not Reported | 11  | 6  | 19  |

| Reporting group values                        | Non-gBRCA Placebo | FE sub-study:<br>Fasted/fed | FE sub-study:<br>Fed/fasted |
|-----------------------------------------------|-------------------|-----------------------------|-----------------------------|
| Number of subjects                            | 116               | 8                           | 9                           |
| Age Categorical<br>Units: Participants        |                   |                             |                             |
| <=18 years                                    | 0                 | 0                           | 0                           |
| Between 18 and 64 years                       | 69                | 5                           | 5                           |
| >=65 years                                    | 47                | 3                           | 4                           |
| Sex: Female, Male<br>Units: Participants      |                   |                             |                             |
| Female                                        | 116               | 8                           | 9                           |
| Male                                          | 0                 | 0                           | 0                           |
| Race/Ethnicity, Customized<br>Units: Subjects |                   |                             |                             |
| American Indian or Alaska Native              | 0                 | 0                           | 0                           |
| Asian                                         | 4                 | 0                           | 0                           |
| Native Hawaiian or Other Pacific Islander     | 0                 | 1                           | 0                           |
| Black or African American                     | 1                 | 1                           | 0                           |
| White                                         | 101               | 6                           | 9                           |
| Unknown or Not Reported                       | 10                | 0                           | 0                           |

| Reporting group values                        | QTc sub-study:<br>Niraparib | Total |  |
|-----------------------------------------------|-----------------------------|-------|--|
| Number of subjects                            | 26                          | 596   |  |
| Age Categorical<br>Units: Participants        |                             |       |  |
| <=18 years                                    | 0                           | 0     |  |
| Between 18 and 64 years                       | 16                          | 384   |  |
| >=65 years                                    | 10                          | 212   |  |
| Sex: Female, Male<br>Units: Participants      |                             |       |  |
| Female                                        | 26                          | 596   |  |
| Male                                          | 0                           | 0     |  |
| Race/Ethnicity, Customized<br>Units: Subjects |                             |       |  |
| American Indian or Alaska Native              | 1                           | 2     |  |
| Asian                                         | 1                           | 20    |  |
| Native Hawaiian or Other Pacific Islander     | 0                           | 1     |  |
| Black or African American                     | 3                           | 11    |  |
| White                                         | 21                          | 516   |  |
| Unknown or Not Reported                       | 0                           | 46    |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                            |                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | gBRCA Niraparib             |
| Reporting group description:<br>Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.                                                                                                                                                                  |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | gBRCA Placebo               |
| Reporting group description:<br>Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.                                                                                                                                                                                           |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | Non-gBRCA Niraparib         |
| Reporting group description:<br>Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.                                                                                                                                                                                           |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | Non-gBRCA Placebo           |
| Reporting group description:<br>Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression                                                                                                                                                                                                         |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | FE sub-study: Fasted/fed    |
| Reporting group description:<br>Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods. |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | FE sub-study: Fed/fasted    |
| Reporting group description:<br>Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.                               |                             |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                      | QTc sub-study: Niraparib    |
| Reporting group description:<br>Participants received Niraparib 300 mg once daily orally.                                                                                                                                                                                                                                                                                  |                             |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                 | non-gBRCAmut HRD+ Niraparib |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                  | Sub-group analysis          |
| Subject analysis set description:<br>Niraparib (300 mg) once daily in 28-day cycles until disease progression in participants with homologous recombination deficiency-positive (HRD+) tumors Niraparib vs. Placebo 2:1 ratio                                                                                                                                              |                             |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                 | non-gBRCAmut HRD+ Placebo   |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                  | Sub-group analysis          |
| Subject analysis set description:<br>Placebo once daily in 28-day cycles until disease progression patients with homologous recombination deficiency-positive (HRD+) tumors Niraparib vs. Placebo 2:1 ratio                                                                                                                                                                |                             |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                 | non-gBRCA Niraparib         |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                  | Sub-group analysis          |
| Subject analysis set description:<br>Niraparib (300 mg) once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio                                                                                                                                                                                   |                             |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                 | non-gBRCA Placebo           |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                  | Sub-group analysis          |
| Subject analysis set description:<br>Placebo once daily in 28-day cycles until disease progression in patients without germline BRCA mutation Niraparib vs. Placebo 2:1 ratio                                                                                                                                                                                              |                             |
| Subject analysis set title                                                                                                                                                                                                                                                                                                                                                 | non-gBRCA Niraparib         |
| Subject analysis set type                                                                                                                                                                                                                                                                                                                                                  | Sub-group analysis          |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | non-gBRCA Niraparib |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | non-gBRCA Placebo  |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | FE Niraparib Fasted |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants received Niraparib 300 mg in fasted condition

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | FE Niraparib Fed   |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants received Niraparib 300 mg in fed condition

|                            |                     |
|----------------------------|---------------------|
| Subject analysis set title | FE Niraparib Fasted |
| Subject analysis set type  | Sub-group analysis  |

Subject analysis set description:

Participants received Niraparib 300 mg in fasted condition

|                            |                    |
|----------------------------|--------------------|
| Subject analysis set title | FE Niraparib Fed   |
| Subject analysis set type  | Sub-group analysis |

Subject analysis set description:

Participants received Niraparib 300 mg in fed condition

### **Primary: Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer gene (BRCA) Mutation (gBRCA)**

|                 |                                                                                                                   |
|-----------------|-------------------------------------------------------------------------------------------------------------------|
| End point title | Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer gene (BRCA) Mutation (gBRCA) <sup>[1]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------------------------|

End point description:

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, which was performed in a blinded fashion. Intent-to-treat population was defined as all randomized participants with participants analyzed according to the study drug assigned via randomization. 99999 indicates Upper limit of confidence interval (CI) was not estimable as upper limits of CI for survivor function were above 0.5 (SAS PROC LIFETEST).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib    | gBRCA Placebo     |  |  |
|----------------------------------|--------------------|-------------------|--|--|
| Subject group type               | Reporting group    | Reporting group   |  |  |
| Number of subjects analysed      | 138 <sup>[2]</sup> | 65 <sup>[3]</sup> |  |  |
| Units: months                    |                    |                   |  |  |
| median (confidence interval 95%) | 21 (12.9 to 99999) | 5.5 (3.8 to 7.2)  |  |  |

Notes:

[2] - Intent-to-treat population

[3] - Intent-to-treat population

### **Statistical analyses**

|                                         |                                 |
|-----------------------------------------|---------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1          |
| Comparison groups                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis | 203                             |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           |                                 |
| P-value                                 | < 0.0001 <sup>[4]</sup>         |
| Method                                  | Logrank                         |
| Parameter estimate                      | Hazard ratio (HR)               |
| Point estimate                          | 0.27                            |
| Confidence interval                     |                                 |
| level                                   | 95 %                            |
| sides                                   | 2-sided                         |
| lower limit                             | 0.173                           |
| upper limit                             | 0.41                            |

Notes:

[4] - Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort.

### **Primary: Progression-Free Survival (PFS) in Cohort with No Germline BCRA with homologous recombination deficiency-positive (HRD+) tumors (non-gBRCAmut HRD+)**

|                 |                                                                                                                                                     |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Progression-Free Survival (PFS) in Cohort with No Germline BCRA with homologous recombination deficiency-positive (HRD+) tumors (non-gBRCAmut HRD+) |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, which was performed in a blinded fashion. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days

| <b>End point values</b>          | non-gBRCAmut HRD+ Niraparib | non-gBRCAmut HRD+ Placebo |  |  |
|----------------------------------|-----------------------------|---------------------------|--|--|
| Subject group type               | Subject analysis set        | Subject analysis set      |  |  |
| Number of subjects analysed      | 106 <sup>[5]</sup>          | 56 <sup>[6]</sup>         |  |  |
| Units: months                    |                             |                           |  |  |
| median (confidence interval 95%) | 12.9 (8.1 to 15.9)          | 3.8 (3.5 to 5.7)          |  |  |

Notes:

[5] - Intent-to-treat population

[6] - Intent-to-treat population

### **Statistical analyses**

|                                   |                                               |
|-----------------------------------|-----------------------------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 1                        |
| Comparison groups                 | non-gBRCAmut HRD+ Placebo v non-gBRCAmut HRD+ |

|                                         |                         |
|-----------------------------------------|-------------------------|
|                                         | Niraparib               |
| Number of subjects included in analysis | 162                     |
| Analysis specification                  | Pre-specified           |
| Analysis type                           |                         |
| P-value                                 | < 0.0001 <sup>[7]</sup> |
| Method                                  | Logrank                 |
| Parameter estimate                      | Hazard ratio (HR)       |
| Point estimate                          | 0.38                    |
| Confidence interval                     |                         |
| level                                   | 95 %                    |
| sides                                   | 2-sided                 |
| lower limit                             | 0.243                   |
| upper limit                             | 0.586                   |

Notes:

[7] - Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested

### Primary: Progression-Free Survival (PFS) in Cohort with No Germline BRCA Mutation (non-gBRCA)

|                 |                                                                                      |
|-----------------|--------------------------------------------------------------------------------------|
| End point title | Progression-Free Survival (PFS) in Cohort with No Germline BRCA Mutation (non-gBRCA) |
|-----------------|--------------------------------------------------------------------------------------|

End point description:

PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, which was performed in a blinded fashion.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days

| End point values                 | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|----------------------------------|------------------------|----------------------|--|--|
| Subject group type               | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[8]</sup>     | 116 <sup>[9]</sup>   |  |  |
| Units: Months                    |                        |                      |  |  |
| median (confidence interval 95%) | 9.3 (7.2 to 11.2)      | 3.9 (3.7 to 5.5)     |  |  |

Notes:

[8] - Intent-to-treat population

[9] - Intent-to-treat population

### Statistical analyses

|                            |                                         |
|----------------------------|-----------------------------------------|
| Statistical analysis title | Statistical Analysis 1                  |
| Comparison groups          | non-gBRCA Niraparib v non-gBRCA Placebo |

|                                         |                          |
|-----------------------------------------|--------------------------|
| Number of subjects included in analysis | 350                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           |                          |
| P-value                                 | < 0.0001 <sup>[10]</sup> |
| Method                                  | Logrank                  |
| Parameter estimate                      | Hazard ratio (HR)        |
| Point estimate                          | 0.45                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 0.338                    |
| upper limit                             | 0.607                    |

Notes:

[10] - Two-sided P-value. PFS was independently evaluated in gBRCAmut cohort and non-gBRCAmut cohort. Hierarchical testing: HRD+ subset tested first. If HRD+ subset demonstrated statistical significance, overall non-gBRCA cohort was then tested.

## Secondary: Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

|                        |                                                                                                                                         |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA) <sup>[11]</sup>                                          |
| End point description: | The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death. |
| End point type         | Secondary                                                                                                                               |
| End point timeframe:   | From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days                |

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|----------------------------------|---------------------|--------------------|--|--|
| Subject group type               | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed      | 138 <sup>[12]</sup> | 65 <sup>[13]</sup> |  |  |
| Units: Months                    |                     |                    |  |  |
| median (confidence interval 95%) | 19.1 (14.6 to 21.9) | 8.6 (6.9 to 12.2)  |  |  |

Notes:

[12] - Intent-to-treat population

[13] - Intent-to-treat population

## Statistical analyses

|                            |                                 |
|----------------------------|---------------------------------|
| Statistical analysis title | Statistical Analysis 1          |
| Comparison groups          | gBRCA Niraparib v gBRCA Placebo |

|                                         |                          |
|-----------------------------------------|--------------------------|
| Number of subjects included in analysis | 203                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 0.0005 <sup>[14]</sup> |
| Method                                  | Logrank                  |
| Parameter estimate                      | Hazard ratio (HR)        |
| Point estimate                          | 0.57                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 0.412                    |
| upper limit                             | 0.783                    |

Notes:

[14] - Two-sided P-value.

## Secondary: Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation

|                 |                                                                           |
|-----------------|---------------------------------------------------------------------------|
| End point title | Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation |
|-----------------|---------------------------------------------------------------------------|

End point description:

The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days

| End point values                 | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|----------------------------------|------------------------|----------------------|--|--|
| Subject group type               | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[15]</sup>    | 116 <sup>[16]</sup>  |  |  |
| Units: Months                    |                        |                      |  |  |
| median (confidence interval 95%) | 12.4 (10.9 to 14.5)    | 7.4 (5.9 to 8.7)     |  |  |

Notes:

[15] - Intent-to-treat population

[16] - Intent-to-treat population

## Statistical analyses

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 350                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | < 0.0001 <sup>[17]</sup>                |
| Method                                  | Logrank                                 |
| Parameter estimate                      | Hazard ratio (HR)                       |
| Point estimate                          | 0.58                                    |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.454   |
| upper limit         | 0.74    |

Notes:

[17] - Two-sided P-value.

## Secondary: Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)

|                 |                                                                                          |
|-----------------|------------------------------------------------------------------------------------------|
| End point title | Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA) <sup>[18]</sup> |
|-----------------|------------------------------------------------------------------------------------------|

End point description:

Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|----------------------------------|---------------------|--------------------|--|--|
| Subject group type               | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed      | 138 <sup>[19]</sup> | 65 <sup>[20]</sup> |  |  |
| Units: Months                    |                     |                    |  |  |
| median (confidence interval 95%) | 20.0 (16.2 to 23.3) | 9.4 (7.9 to 10.4)  |  |  |

Notes:

[19] - Intent-to-treat population

[20] - Intent-to-treat population

## Statistical analyses

|                                         |                                 |
|-----------------------------------------|---------------------------------|
| Statistical analysis title              | Statistical Analysis 1          |
| Comparison groups                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis | 203                             |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           | superiority                     |
| P-value                                 | < 0.0001 <sup>[21]</sup>        |
| Method                                  | Logrank                         |
| Parameter estimate                      | Hazard ratio (HR)               |
| Point estimate                          | 0.39                            |
| Confidence interval                     |                                 |
| level                                   | 95 %                            |
| sides                                   | 2-sided                         |
| lower limit                             | 0.268                           |
| upper limit                             | 0.561                           |

Notes:

[21] - Two-sided P-value.

## Secondary: Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation

|                 |                                                                     |
|-----------------|---------------------------------------------------------------------|
| End point title | Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation |
|-----------------|---------------------------------------------------------------------|

End point description:

Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days

| End point values                 | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|----------------------------------|------------------------|----------------------|--|--|
| Subject group type               | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[22]</sup>    | 116 <sup>[23]</sup>  |  |  |
| Units: Months                    |                        |                      |  |  |
| median (confidence interval 95%) | 13.4 (11.3 to 14.8)    | 8.7 (6.9 to 10.0)    |  |  |

Notes:

[22] - Intent-to-treat population

[23] - Intent-to-treat population

## Statistical analyses

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| Statistical analysis title              | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 350                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | < 0.0001 <sup>[24]</sup>                |
| Method                                  | Logrank                                 |
| Parameter estimate                      | Hazard ratio (HR)                       |
| Point estimate                          | 0.56                                    |
| Confidence interval                     |                                         |
| level                                   | 95 %                                    |
| sides                                   | 2-sided                                 |
| lower limit                             | 0.428                                   |
| upper limit                             | 0.727                                   |

Notes:

[24] - Two-sided P-value.

## Secondary: Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)

|                 |                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------|
| End point title | Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA) <sup>[25]</sup> |
|-----------------|-------------------------------------------------------------------------------------------|

End point description:

Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier

date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib     | gBRCA Placebo       |  |  |
|----------------------------------|---------------------|---------------------|--|--|
| Subject group type               | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed      | 138 <sup>[26]</sup> | 65 <sup>[27]</sup>  |  |  |
| Units: Months                    |                     |                     |  |  |
| median (confidence interval 95%) | 29.9 (24.8 to 33.4) | 22.7 (19.5 to 25.9) |  |  |

Notes:

[26] - Intent-to-treat population

[27] - Intent-to-treat population

## Statistical analyses

| Statistical analysis title              | Statistical Analysis 1          |
|-----------------------------------------|---------------------------------|
| Comparison groups                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis | 203                             |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           | superiority                     |
| P-value                                 | = 0.0302 <sup>[28]</sup>        |
| Method                                  | Logrank                         |
| Parameter estimate                      | Hazard ratio (HR)               |
| Point estimate                          | 0.7                             |
| Confidence interval                     |                                 |
| level                                   | 95 %                            |
| sides                                   | 2-sided                         |
| lower limit                             | 0.5                             |
| upper limit                             | 0.968                           |

Notes:

[28] - Two-sided P-value.

## Secondary: Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation

|                 |                                                                      |
|-----------------|----------------------------------------------------------------------|
| End point title | Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation |
|-----------------|----------------------------------------------------------------------|

End point description:

Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From treatment randomization to the earlier of the date of disease progression on the next anti-cancer

| End point values                 | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|----------------------------------|------------------------|----------------------|--|--|
| Subject group type               | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[29]</sup>    | 116 <sup>[30]</sup>  |  |  |
| Units: Months                    |                        |                      |  |  |
| median (confidence interval 95%) | 19.5 (17.1 to 22.3)    | 16.1 (13.6 to 22.8)  |  |  |

Notes:

[29] - Intent-to-treat population

[30] - Intent-to-treat population

### Statistical analyses

| Statistical analysis title              | Statistical Analysis 1                  |
|-----------------------------------------|-----------------------------------------|
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 350                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | = 0.0748 <sup>[31]</sup>                |
| Method                                  | Logrank                                 |
| Parameter estimate                      | Hazard ratio (HR)                       |
| Point estimate                          | 0.8                                     |
| Confidence interval                     |                                         |
| level                                   | 95 %                                    |
| sides                                   | 2-sided                                 |
| lower limit                             | 0.627                                   |
| upper limit                             | 1.022                                   |

Notes:

[31] - Two-sided P-value.

### Secondary: Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)

|                        |                                                                                                |
|------------------------|------------------------------------------------------------------------------------------------|
| End point title        | Overall Survival in Cohort With Germline BRCA Mutation (gBRCA) <sup>[32]</sup>                 |
| End point description: | Overall survival was defined as the date of randomization to the date of death by any cause.   |
| End point type         | Secondary                                                                                      |
| End point timeframe:   | From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days |

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib     | gBRCA Placebo       |  |  |
|----------------------------------|---------------------|---------------------|--|--|
| Subject group type               | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed      | 138 <sup>[33]</sup> | 65 <sup>[34]</sup>  |  |  |
| Units: Months                    |                     |                     |  |  |
| median (confidence interval 95%) | 40.9 (34.9 to 52.9) | 38.1 (27.6 to 47.3) |  |  |

Notes:

[33] - Intent-to-treat population

[34] - Intent-to-treat population

### Statistical analyses

| Statistical analysis title              | Statistical Analysis 1          |
|-----------------------------------------|---------------------------------|
| Comparison groups                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis | 203                             |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           | superiority                     |
| P-value                                 | = 0.358 <sup>[35]</sup>         |
| Method                                  | Logrank                         |
| Parameter estimate                      | Hazard ratio (HR)               |
| Point estimate                          | 0.85                            |
| Confidence interval                     |                                 |
| level                                   | 95 %                            |
| sides                                   | 2-sided                         |
| lower limit                             | 0.606                           |
| upper limit                             | 1.198                           |

Notes:

[35] - Two-sided P-value.

### Secondary: Overall Survival in Cohort With No Germline BRCA Mutation

|                        |                                                                                                |
|------------------------|------------------------------------------------------------------------------------------------|
| End point title        | Overall Survival in Cohort With No Germline BRCA Mutation                                      |
| End point description: | Overall survival was defined as the date of randomization to the date of death by any cause.   |
| End point type         | Secondary                                                                                      |
| End point timeframe:   | From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days |

| End point values                 | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|----------------------------------|----------------------|----------------------|--|--|
| Subject group type               | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[36]</sup>  | 116 <sup>[37]</sup>  |  |  |
| Units: Months                    |                      |                      |  |  |
| median (confidence interval 95%) | 31.0 (27.8 to 35.6)  | 34.8 (27.9 to 41.4)  |  |  |

Notes:

[36] - Intent-to-treat population

[37] - Intent-to-treat population

### Statistical analyses

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 350                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | = 0.6868 <sup>[38]</sup>                |
| Method                                  | Logrank                                 |
| Parameter estimate                      | Hazard ratio (HR)                       |
| Point estimate                          | 1.06                                    |
| Confidence interval                     |                                         |
| level                                   | 95 %                                    |
| sides                                   | 2-sided                                 |
| lower limit                             | 0.813                                   |
| upper limit                             | 1.369                                   |

Notes:

[38] - Two-sided P-value.

## Secondary: Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)

|                 |                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------|
| End point title | Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA) <sup>[39]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------|

End point description:

TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                 | gBRCA Niraparib     | gBRCA Placebo       |  |  |
|----------------------------------|---------------------|---------------------|--|--|
| Subject group type               | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed      | 138 <sup>[40]</sup> | 65 <sup>[41]</sup>  |  |  |
| Units: Months                    |                     |                     |  |  |
| median (confidence interval 95%) | 29.7 (23.3 to 33.4) | 19.6 (14.4 to 25.5) |  |  |

Notes:

[40] - Intent-to-treat population

[41] - Intent-to-treat population

## Statistical analyses

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 1          |
| Comparison groups                 | gBRCA Niraparib v gBRCA Placebo |

|                                         |                          |
|-----------------------------------------|--------------------------|
| Number of subjects included in analysis | 203                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 0.0061 <sup>[42]</sup> |
| Method                                  | Logrank                  |
| Parameter estimate                      | Hazard ratio (HR)        |
| Point estimate                          | 0.63                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 0.451                    |
| upper limit                             | 0.878                    |

Notes:

[42] - Two-sided P-value.

## Secondary: Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation

|                 |                                                                            |
|-----------------|----------------------------------------------------------------------------|
| End point title | Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation |
|-----------------|----------------------------------------------------------------------------|

End point description:

TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days

| End point values                 | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|----------------------------------|----------------------|----------------------|--|--|
| Subject group type               | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed      | 234 <sup>[43]</sup>  | 116 <sup>[44]</sup>  |  |  |
| Units: Months                    |                      |                      |  |  |
| median (confidence interval 95%) | 20.3 (18.0 to 23.4)  | 16.7 (14.9 to 21.3)  |  |  |

Notes:

[43] - Intent-to-treat population

[44] - Intent-to-treat population

## Statistical analyses

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| Statistical analysis title              | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 350                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | = 0.1674 <sup>[45]</sup>                |
| Method                                  | Logrank                                 |
| Parameter estimate                      | Hazard ratio (HR)                       |
| Point estimate                          | 0.84                                    |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.654   |
| upper limit         | 1.077   |

Notes:

[45] - Two-sided P-value.

### Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2

|                 |                                                                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2 <sup>[46]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|--------------------------------------|---------------------|--------------------|--|--|
| Subject group type                   | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed          | 114 <sup>[47]</sup> | 55 <sup>[48]</sup> |  |  |
| Units: Scores on a scale             |                     |                    |  |  |
| arithmetic mean (standard deviation) | -0.8 (± 4.58)       | -0.3 (± 3.19)      |  |  |

Notes:

[47] - Intent-to-treat population

[48] - Intent-to-treat population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4

|                 |                                                                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4 <sup>[49]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the

number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|--------------------------------------|---------------------|--------------------|--|--|
| Subject group type                   | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed          | 109 <sup>[50]</sup> | 43 <sup>[51]</sup> |  |  |
| Units: Scores on a scale             |                     |                    |  |  |
| arithmetic mean (standard deviation) | -0.1 (± 4.07)       | -0.3 (± 3.88)      |  |  |

Notes:

[50] - Intent-to-treat population

[51] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6

|                 |                                                                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6 <sup>[52]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib    | gBRCA Placebo      |  |  |
|--------------------------------------|--------------------|--------------------|--|--|
| Subject group type                   | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed          | 95 <sup>[53]</sup> | 36 <sup>[54]</sup> |  |  |
| Units: Scores on a scale             |                    |                    |  |  |
| arithmetic mean (standard deviation) | 0.5 (± 3.77)       | -0.5 (± 4.27)      |  |  |

Notes:

[53] - Intent-to-treat population

[54] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at post-progression

|                 |                                                                                                                                                        |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at post-progression <sup>[55]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Cycle 1 Day 1, Each cycle was of 28 days) and up to 7 years, 7 months and 4 days

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib    | gBRCA Placebo      |  |  |
|--------------------------------------|--------------------|--------------------|--|--|
| Subject group type                   | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed          | 80 <sup>[56]</sup> | 37 <sup>[57]</sup> |  |  |
| Units: Scores on a scale             |                    |                    |  |  |
| arithmetic mean (standard deviation) | -0.751 (± 4.4342)  | -1.324 (± 4.5034)  |  |  |

Notes:

[56] - Intent-to-treat population

[57] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2

|                 |                                                         |
|-----------------|---------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer |
|-----------------|---------------------------------------------------------|

## End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

| End point values                     | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 181 <sup>[58]</sup>  | 97 <sup>[59]</sup>   |  |  |
| Units: Scores on a scale             |                      |                      |  |  |
| arithmetic mean (standard deviation) | -1.0 (± 3.79)        | -0.3 (± 2.84)        |  |  |

## Notes:

[58] - Intent-to-treat population

[59] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4

|                 |                                                                                                                                  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

## End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

| End point values                     | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|--------------------------------------|------------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed          | 150 <sup>[60]</sup>    | 77 <sup>[61]</sup>   |  |  |
| Units: Scores on a scale             |                        |                      |  |  |
| arithmetic mean (standard deviation) | -0.7 (± 4.16)          | -0.9 (± 4.23)        |  |  |

Notes:

[60] - Intent-to-treat population

[61] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6

|                 |                                                                                                                                  |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6 |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

| End point values                     | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|--------------------------------------|------------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed          | 124 <sup>[62]</sup>    | 50 <sup>[63]</sup>   |  |  |
| Units: Scores on a scale             |                        |                      |  |  |
| arithmetic mean (standard deviation) | -0.2 (± 3.76)          | -0.9 (± 3.43)        |  |  |

Notes:

[62] - Intent-to-treat population

[63] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at post-progression

|                 |                                                                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at post-progression |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of

symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                                                                     |           |
|---------------------------------------------------------------------|-----------|
| End point type                                                      | Secondary |
| End point timeframe:                                                |           |
| Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days |           |

| End point values                     | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 146 <sup>[64]</sup>  | 82 <sup>[65]</sup>   |  |  |
| Units: Scores on a scale             |                      |                      |  |  |
| arithmetic mean (standard deviation) | -2.595 (± 5.5700)    | -1.801 (± 4.0290)    |  |  |

Notes:

[64] - Intent-to-treat population

[65] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2

|                 |                                                                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2 <sup>[66]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                                                                         |           |
|-------------------------------------------------------------------------|-----------|
| End point type                                                          | Secondary |
| End point timeframe:                                                    |           |
| Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days) |           |

Notes:

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|--------------------------------------|---------------------|--------------------|--|--|
| Subject group type                   | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed          | 118 <sup>[67]</sup> | 59 <sup>[68]</sup> |  |  |
| Units: Scores on a scale             |                     |                    |  |  |
| arithmetic mean (standard deviation) | -0.008 (± 0.1092)   | -0.008 (± 0.1354)  |  |  |

Notes:

[67] - Intent-to-treat population

[68] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4

|                 |                                                                                          |
|-----------------|------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4 <sup>[69]</sup> |
|-----------------|------------------------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)

Notes:

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|--------------------------------------|---------------------|--------------------|--|--|
| Subject group type                   | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed          | 113 <sup>[70]</sup> | 44 <sup>[71]</sup> |  |  |
| Units: Scores on a scale             |                     |                    |  |  |
| arithmetic mean (standard deviation) | -0.010 (± 0.1225)   | -0.035 (± 0.1156)  |  |  |

Notes:

[70] - Intent-to-treat population

[71] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6

|                 |                                                                                          |
|-----------------|------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6 <sup>[72]</sup> |
|-----------------|------------------------------------------------------------------------------------------|

---

**End point description:**

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)

---

**Notes:**

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib    | gBRCA Placebo      |  |  |
|--------------------------------------|--------------------|--------------------|--|--|
| Subject group type                   | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed          | 99 <sup>[73]</sup> | 36 <sup>[74]</sup> |  |  |
| Units: Scores on a scale             |                    |                    |  |  |
| arithmetic mean (standard deviation) | 0.002 (± 0.1116)   | -0.004 (± 0.1463)  |  |  |

**Notes:**

[73] - Intent-to-treat population

[74] - Intent-to-treat population

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at post-progression**

---

|                 |                                                                                                   |
|-----------------|---------------------------------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at post-progression <sup>[75]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------|

---

**End point description:**

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

**End point timeframe:**

Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days

---

**Notes:**

[75] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values                     | gBRCA Niraparib    | gBRCA Placebo      |  |  |
|--------------------------------------|--------------------|--------------------|--|--|
| Subject group type                   | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed          | 81 <sup>[76]</sup> | 38 <sup>[77]</sup> |  |  |
| Units: Scores on a scale             |                    |                    |  |  |
| arithmetic mean (standard deviation) | -0.041 (± 0.1192)  | -0.013 (± 0.1580)  |  |  |

Notes:

[76] - Intent-to-treat population

[77] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2 |
|-----------------|-----------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)

| End point values                     | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 185 <sup>[78]</sup>  | 96 <sup>[79]</sup>   |  |  |
| Units: Scores on a scale             |                      |                      |  |  |
| arithmetic mean (standard deviation) | -0.007 (± 0.1013)    | -0.011 (± 0.1015)    |  |  |

Notes:

[78] - Intent-to-treat population

[79] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4 |
|-----------------|-----------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument.

The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                                                                         |           |
|-------------------------------------------------------------------------|-----------|
| End point type                                                          | Secondary |
| End point timeframe:                                                    |           |
| Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days) |           |

| End point values                     | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 155 <sup>[80]</sup>  | 80 <sup>[81]</sup>   |  |  |
| Units: Scores on a scale             |                      |                      |  |  |
| arithmetic mean (standard deviation) | -0.004 (± 0.1077)    | -0.014 (± 0.0870)    |  |  |

Notes:

[80] - Intent-to-treat population

[81] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6 |
|-----------------|-----------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                                                                         |           |
|-------------------------------------------------------------------------|-----------|
| End point type                                                          | Secondary |
| End point timeframe:                                                    |           |
| Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days) |           |

| End point values                     | non-gBRCA Placebo    | non-gBRCA Niraparib  |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 50 <sup>[82]</sup>   | 127 <sup>[83]</sup>  |  |  |
| Units: Scores on a scale             |                      |                      |  |  |
| arithmetic mean (standard deviation) | -0.011 (± 0.0949)    | 0.005 (± 0.1097)     |  |  |

Notes:

[82] - Intent-to-treat population

[83] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at post-progression

|                 |                                                                                      |
|-----------------|--------------------------------------------------------------------------------------|
| End point title | Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at post-progression |
|-----------------|--------------------------------------------------------------------------------------|

End point description:

EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days

| End point values                     | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|--------------------------------------|------------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed          | 149 <sup>[84]</sup>    | 84 <sup>[85]</sup>   |  |  |
| Units: Scores on a scale             |                        |                      |  |  |
| arithmetic mean (standard deviation) | -0.047 (±<br>0.1355)   | -0.050 (±<br>0.1351) |  |  |

Notes:

[84] - Intent-to-treat population

[85] - Intent-to-treat population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Baseline

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Baseline <sup>[86]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater

than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| At Baseline          |           |

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|-----------------------------|---------------------|--------------------|--|--|
| Subject group type          | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed | 138 <sup>[87]</sup> | 65 <sup>[88]</sup> |  |  |
| Units: Participants         |                     |                    |  |  |
| Feet, 0-Not at all          | 47                  | 26                 |  |  |
| Feet, 1-A little bit        | 32                  | 12                 |  |  |
| Feet, 2-Somewhat            | 24                  | 9                  |  |  |
| Feet, 3-Quite a bit         | 21                  | 10                 |  |  |
| Feet, 4-Very much           | 9                   | 6                  |  |  |
| Hands, 0-Not at all         | 80                  | 37                 |  |  |
| Hands, 1-A little bit       | 28                  | 13                 |  |  |
| Hands, 2-Somewhat           | 8                   | 6                  |  |  |
| Hands, 3-Quite a bit        | 14                  | 5                  |  |  |
| Hands, 4-Very much          | 3                   | 2                  |  |  |

Notes:

[87] - Intent-to-treat population

[88] - Intent-to-treat population

## Statistical analyses

|                                                    |                                 |
|----------------------------------------------------|---------------------------------|
| Statistical analysis title                         | Statistical Analysis 1          |
| Statistical analysis description:                  |                                 |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                 |
| Comparison groups                                  | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis            | 203                             |
| Analysis specification                             | Pre-specified                   |
| Analysis type                                      | superiority                     |
| P-value                                            | = 0.7969                        |
| Method                                             | Pearson's Chi-squared test      |

|                                                     |                                 |
|-----------------------------------------------------|---------------------------------|
| Statistical analysis title                          | Statistical Analysis 1          |
| Statistical analysis description:                   |                                 |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                 |
| Comparison groups                                   | gBRCA Niraparib v gBRCA Placebo |

|                                         |                            |
|-----------------------------------------|----------------------------|
| Number of subjects included in analysis | 203                        |
| Analysis specification                  | Pre-specified              |
| Analysis type                           | superiority                |
| P-value                                 | = 0.8794                   |
| Method                                  | Pearson's Chi-squared test |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 2

|                 |                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 2 <sup>[89]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Cycle 2 (Each cycle was of 28 days)

Notes:

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|-----------------------------|---------------------|--------------------|--|--|
| Subject group type          | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed | 132 <sup>[90]</sup> | 64 <sup>[91]</sup> |  |  |
| Units: Participants         |                     |                    |  |  |
| Feet, 0-Not at all          | 48                  | 25                 |  |  |
| Feet, 1-A little bit        | 22                  | 5                  |  |  |
| Feet, 2-Somewhat            | 17                  | 15                 |  |  |
| Feet, 3-Quite a bit         | 20                  | 10                 |  |  |
| Feet, 4-Very much           | 8                   | 3                  |  |  |
| Hands, 0-Not at all         | 73                  | 31                 |  |  |
| Hands, 1-A little bit       | 19                  | 16                 |  |  |
| Hands, 2-Somewhat           | 13                  | 6                  |  |  |
| Hands, 3-Quite a bit        | 7                   | 2                  |  |  |
| Hands, 4-Very much          | 3                   | 2                  |  |  |

Notes:

[90] - Intent-to-treat population

[91] - Intent-to-treat population

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet

|                                         |                                 |
|-----------------------------------------|---------------------------------|
| Comparison groups                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis | 196                             |
| Analysis specification                  | Pre-specified                   |
| Analysis type                           | superiority                     |
| P-value                                 | = 0.2399                        |
| Method                                  | Pearson's Chi-squared test      |

|                                                     |                                 |
|-----------------------------------------------------|---------------------------------|
| <b>Statistical analysis title</b>                   | Statistical Analysis 1          |
| Statistical analysis description:                   |                                 |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                 |
| Comparison groups                                   | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis             | 196                             |
| Analysis specification                              | Pre-specified                   |
| Analysis type                                       | superiority                     |
| P-value                                             | = 0.4584                        |
| Method                                              | Pearson's Chi-squared test      |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 4

|                 |                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 4 <sup>[92]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Cycle 4 (Each cycle was of 28 days)

Notes:

[92] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA Niraparib     | gBRCA Placebo      |  |  |
|-----------------------------|---------------------|--------------------|--|--|
| Subject group type          | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed | 120 <sup>[93]</sup> | 54 <sup>[94]</sup> |  |  |
| Units: Participants         |                     |                    |  |  |
| Feet, 0-Not at all          | 47                  | 20                 |  |  |
| Feet, 1-A little bit        | 22                  | 6                  |  |  |
| Feet, 2-Somewhat            | 20                  | 7                  |  |  |
| Feet, 3-Quite a bit         | 15                  | 8                  |  |  |
| Feet, 4-Very much           | 6                   | 2                  |  |  |

|                       |    |    |  |  |
|-----------------------|----|----|--|--|
| Hands, 0-Not at all   | 70 | 29 |  |  |
| Hands, 1-A little bit | 18 | 6  |  |  |
| Hands, 2-Somewhat     | 16 | 3  |  |  |
| Hands, 3-Quite a bit  | 4  | 4  |  |  |
| Hands, 4-Very much    | 2  | 1  |  |  |

Notes:

[93] - Intent-to-treat population

[94] - Intent-to-treat population

## Statistical analyses

|                                                     |                                 |
|-----------------------------------------------------|---------------------------------|
| <b>Statistical analysis title</b>                   | Statistical Analysis 1          |
| Statistical analysis description:                   |                                 |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                 |
| Comparison groups                                   | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis             | 174                             |
| Analysis specification                              | Pre-specified                   |
| Analysis type                                       | superiority                     |
| P-value                                             | = 0.4705                        |
| Method                                              | Pearson's Chi-squared test      |

|                                                    |                                 |
|----------------------------------------------------|---------------------------------|
| <b>Statistical analysis title</b>                  | Statistical Analysis 1          |
| Statistical analysis description:                  |                                 |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                 |
| Comparison groups                                  | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis            | 174                             |
| Analysis specification                             | Pre-specified                   |
| Analysis type                                      | superiority                     |
| P-value                                            | = 0.8566                        |
| Method                                             | Pearson's Chi-squared test      |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 6

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at Cycle 6 <sup>[95]</sup> |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                          |
| A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed. |                                                                                                                          |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary                                                                                                                |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                          |
| At Cycle 6 (Each cycle was of 28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                          |

Notes:

[95] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA<br>Niraparib  | gBRCA Placebo      |  |  |
|-----------------------------|---------------------|--------------------|--|--|
| Subject group type          | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed | 105 <sup>[96]</sup> | 41 <sup>[97]</sup> |  |  |
| Units: Participants         |                     |                    |  |  |
| Feet, 0-Not at all          | 44                  | 17                 |  |  |
| Feet, 1-A little bit        | 17                  | 5                  |  |  |
| Feet, 2-Somewhat            | 13                  | 7                  |  |  |
| Feet, 3-Quite a bit         | 15                  | 5                  |  |  |
| Feet, 4-Very much           | 9                   | 2                  |  |  |
| Hands, 0-Not at all         | 54                  | 21                 |  |  |
| Hands, 1-A little bit       | 25                  | 8                  |  |  |
| Hands, 2-Somewhat           | 10                  | 4                  |  |  |
| Hands, 3-Quite a bit        | 6                   | 2                  |  |  |
| Hands, 4-Very much          | 2                   | 1                  |  |  |

Notes:

[96] - Intent-to-treat population

[97] - Intent-to-treat population

## Statistical analyses

| Statistical analysis title                                                              | Statistical Analysis 1          |
|-----------------------------------------------------------------------------------------|---------------------------------|
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                 |
| Comparison groups                                                                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis                                                 | 146                             |
| Analysis specification                                                                  | Pre-specified                   |
| Analysis type                                                                           | superiority                     |
| P-value                                                                                 | = 0.8521                        |
| Method                                                                                  | Pearson's Chi-squared test      |

| Statistical analysis title                                                               | Statistical Analysis 1          |
|------------------------------------------------------------------------------------------|---------------------------------|
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                 |
| Comparison groups                                                                        | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis                                                  | 146                             |
| Analysis specification                                                                   | Pre-specified                   |
| Analysis type                                                                            | superiority                     |
| P-value                                                                                  | = 0.9923                        |
| Method                                                                                   | Pearson's Chi-squared test      |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at post-progression

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Number of participants with response to Neuropathy questionnaire in Cohort With Germline BRCA at post-progression <sup>[98]</sup> |
| End point description:<br>A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed. |                                                                                                                                   |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Secondary                                                                                                                         |
| End point timeframe:<br>Up to 7 years, 7 months and 4 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                   |

### Notes:

[98] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA Niraparib     | gBRCA Placebo       |  |  |
|-----------------------------|---------------------|---------------------|--|--|
| Subject group type          | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed | 104 <sup>[99]</sup> | 49 <sup>[100]</sup> |  |  |
| Units: Participants         |                     |                     |  |  |
| Feet, 0-Not at all          | 31                  | 15                  |  |  |
| Feet, 1-A little bit        | 20                  | 9                   |  |  |
| Feet, 2-Somewhat            | 7                   | 3                   |  |  |
| Feet, 3-Quite a bit         | 15                  | 7                   |  |  |
| Feet, 4-Very much           | 7                   | 3                   |  |  |
| Hands, 0-Not at all         | 44                  | 26                  |  |  |
| Hands, 1-A little bit       | 18                  | 4                   |  |  |
| Hands, 2-Somewhat           | 8                   | 3                   |  |  |
| Hands, 3-Quite a bit        | 7                   | 4                   |  |  |
| Hands, 4-Very much          | 3                   | 0                   |  |  |

### Notes:

[99] - Intent-to-treat population

[100] - Intent-to-treat population

## Statistical analyses

|                                                                                          |                                 |
|------------------------------------------------------------------------------------------|---------------------------------|
| Statistical analysis title                                                               | Statistical Analysis 1          |
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                 |
| Comparison groups                                                                        | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis                                                  | 153                             |
| Analysis specification                                                                   | Pre-specified                   |
| Analysis type                                                                            | superiority                     |
| P-value                                                                                  | = 0.3518                        |
| Method                                                                                   | Pearson's Chi-squared test      |

|                                                                                         |                                 |
|-----------------------------------------------------------------------------------------|---------------------------------|
| <b>Statistical analysis title</b>                                                       | Statistical Analysis 1          |
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                 |
| Comparison groups                                                                       | gBRCA Niraparib v gBRCA Placebo |
| Number of subjects included in analysis                                                 | 153                             |
| Analysis specification                                                                  | Pre-specified                   |
| Analysis type                                                                           | superiority                     |
| P-value                                                                                 | = 0.9997                        |
| Method                                                                                  | Pearson's Chi-squared test      |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Baseline

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Baseline |
| End point description:<br>A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date. |                                                                                                              |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary                                                                                                    |
| End point timeframe:<br>At Baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                              |

| End point values            | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed | 234 <sup>[101]</sup> | 116 <sup>[102]</sup> |  |  |
| Units: Participants         |                      |                      |  |  |
| Feet, 0-Not at all          | 71                   | 40                   |  |  |
| Feet, 1-A little bit        | 58                   | 26                   |  |  |
| Feet, 2-Somewhat            | 37                   | 16                   |  |  |
| Feet, 3-Quite a bit         | 43                   | 21                   |  |  |
| Feet, 4-Very much           | 18                   | 9                    |  |  |
| Hands, 0-Not at all         | 120                  | 48                   |  |  |
| Hands, 1-A little bit       | 56                   | 37                   |  |  |
| Hands, 2-Somewhat           | 28                   | 12                   |  |  |
| Hands, 3-Quite a bit        | 15                   | 11                   |  |  |
| Hands, 4-Very much          | 8                    | 2                    |  |  |

Notes:

[101] - Intent-to-treat population

[102] - Intent-to-treat population

## Statistical analyses

|                                                     |                                         |
|-----------------------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>                   | Statistical Analysis 1                  |
| Statistical analysis description:                   |                                         |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                         |
| Comparison groups                                   | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis             | 350                                     |
| Analysis specification                              | Pre-specified                           |
| Analysis type                                       | superiority                             |
| P-value                                             | = 0.2502                                |
| Method                                              | Pearson's Chi-squared test              |

|                                                    |                                         |
|----------------------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>                  | Statistical Analysis 1                  |
| Statistical analysis description:                  |                                         |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                         |
| Comparison groups                                  | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis            | 350                                     |
| Analysis specification                             | Pre-specified                           |
| Analysis type                                      | superiority                             |
| P-value                                            | = 0.9367                                |
| Method                                             | Pearson's Chi-squared test              |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 2

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 2 |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                             |
| A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed |                                                                                                             |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary                                                                                                   |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                             |
| At Cycle 2 (Each cycle was of 28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                             |

| End point values            | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|-----------------------------|------------------------|----------------------|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed | 212 <sup>[103]</sup>   | 113 <sup>[104]</sup> |  |  |
| Units: Participants         |                        |                      |  |  |
| Feet, 0-Not at all          | 69                     | 32                   |  |  |
| Feet, 1-A little bit        | 39                     | 17                   |  |  |
| Feet, 2-Somewhat            | 30                     | 22                   |  |  |
| Feet, 3-Quite a bit         | 34                     | 18                   |  |  |
| Feet, 4-Very much           | 9                      | 8                    |  |  |
| Hands, 0-Not at all         | 100                    | 44                   |  |  |
| Hands, 1-A little bit       | 38                     | 24                   |  |  |
| Hands, 2-Somewhat           | 20                     | 19                   |  |  |
| Hands, 3-Quite a bit        | 17                     | 5                    |  |  |
| Hands, 4-Very much          | 4                      | 3                    |  |  |

Notes:

[103] - Intent-to-treat population

[104] - Intent-to-treat population

## Statistical analyses

| Statistical analysis title                                                               | Statistical Analysis 1                  |
|------------------------------------------------------------------------------------------|-----------------------------------------|
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                         |
| Comparison groups                                                                        | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis                                                  | 325                                     |
| Analysis specification                                                                   | Pre-specified                           |
| Analysis type                                                                            | superiority                             |
| P-value                                                                                  | = 0.164                                 |
| Method                                                                                   | Pearson's Chi-squared test              |

| Statistical analysis title                                                              | Statistical Analysis 1                  |
|-----------------------------------------------------------------------------------------|-----------------------------------------|
| Statistical analysis description:<br>Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                         |
| Comparison groups                                                                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis                                                 | 325                                     |
| Analysis specification                                                                  | Pre-specified                           |
| Analysis type                                                                           | superiority                             |
| P-value                                                                                 | = 0.5037                                |
| Method                                                                                  | Pearson's Chi-squared test              |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 4

|                 |                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 4 |
|-----------------|-------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1)

or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date. Only those participants with data available at indicated time points were analyzed.

|                                        |           |
|----------------------------------------|-----------|
| End point type                         | Secondary |
| End point timeframe:                   |           |
| At Cycle 4 (Each cycle was of 28 days) |           |

| End point values            | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed | 181 <sup>[105]</sup> | 95 <sup>[106]</sup>  |  |  |
| Units: Participants         |                      |                      |  |  |
| Feet, 0-Not at all          | 54                   | 31                   |  |  |
| Feet, 1-A little bit        | 37                   | 16                   |  |  |
| Feet, 2-Somewhat            | 34                   | 17                   |  |  |
| Feet, 3-Quite a bit         | 20                   | 11                   |  |  |
| Feet, 4-Very much           | 9                    | 5                    |  |  |
| Hands, 0-Not at all         | 89                   | 43                   |  |  |
| Hands, 1-A little bit       | 29                   | 21                   |  |  |
| Hands, 2-Somewhat           | 14                   | 10                   |  |  |
| Hands, 3-Quite a bit        | 14                   | 3                    |  |  |
| Hands, 4-Very much          | 6                    | 1                    |  |  |

Notes:

[105] - Intent-to-treat population

[106] - Intent-to-treat population

## Statistical analyses

|                                                     |                                         |
|-----------------------------------------------------|-----------------------------------------|
| Statistical analysis title                          | Statistical Analysis 1                  |
| Statistical analysis description:                   |                                         |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands |                                         |
| Comparison groups                                   | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis             | 276                                     |
| Analysis specification                              | Pre-specified                           |
| Analysis type                                       | superiority                             |
| P-value                                             | = 0.247                                 |
| Method                                              | Pearson's Chi-squared test              |

|                                                    |                                         |
|----------------------------------------------------|-----------------------------------------|
| Statistical analysis title                         | Statistical Analysis 1                  |
| Statistical analysis description:                  |                                         |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                         |
| Comparison groups                                  | non-gBRCA Niraparib v non-gBRCA Placebo |

|                                         |                            |
|-----------------------------------------|----------------------------|
| Number of subjects included in analysis | 276                        |
| Analysis specification                  | Pre-specified              |
| Analysis type                           | superiority                |
| P-value                                 | = 0.9599                   |
| Method                                  | Pearson's Chi-squared test |

## Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 6

|                 |                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at Cycle 6 |
|-----------------|-------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Cycle 6 (Each cycle was of 28 days)

| End point values            | non-gBRCA<br>Niraparib | non-gBRCA<br>Placebo |  |  |
|-----------------------------|------------------------|----------------------|--|--|
| Subject group type          | Subject analysis set   | Subject analysis set |  |  |
| Number of subjects analysed | 144 <sup>[107]</sup>   | 56 <sup>[108]</sup>  |  |  |
| Units: Participants         |                        |                      |  |  |
| Feet, 0-Not at all          | 43                     | 16                   |  |  |
| Feet, 1-A little bit        | 29                     | 10                   |  |  |
| Feet, 2-Somewhat            | 30                     | 11                   |  |  |
| Feet, 3-Quite a bit         | 18                     | 9                    |  |  |
| Feet, 4-Very much           | 5                      | 5                    |  |  |
| Hands, 0-Not at all         | 68                     | 29                   |  |  |
| Hands, 1-A little bit       | 30                     | 10                   |  |  |
| Hands, 2-Somewhat           | 13                     | 6                    |  |  |
| Hands, 3-Quite a bit        | 9                      | 5                    |  |  |
| Hands, 4-Very much          | 3                      | 0                    |  |  |

Notes:

[107] - Intent-to-treat population

[108] - Intent-to-treat population

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Analysis for gBRCA Niraparib vs gBRCA Placebo-Hands

|                   |                                         |
|-------------------|-----------------------------------------|
| Comparison groups | non-gBRCA Niraparib v non-gBRCA Placebo |
|-------------------|-----------------------------------------|

|                                         |                            |
|-----------------------------------------|----------------------------|
| Number of subjects included in analysis | 200                        |
| Analysis specification                  | Pre-specified              |
| Analysis type                           | superiority                |
| P-value                                 | = 0.7459                   |
| Method                                  | Pearson's Chi-squared test |

|                                                    |                                         |
|----------------------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>                  | Statistical Analysis 1                  |
| Statistical analysis description:                  |                                         |
| Analysis for gBRCA Niraparib vs gBRCA Placebo-Feet |                                         |
| Comparison groups                                  | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis            | 200                                     |
| Analysis specification                             | Pre-specified                           |
| Analysis type                                      | superiority                             |
| P-value                                            | = 0.5921                                |
| Method                                             | Pearson's Chi-squared test              |

### Secondary: Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at post-progression

|                 |                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with response to Neuropathy questionnaire in Cohort With no Germline BRCA at post-progression |
|-----------------|----------------------------------------------------------------------------------------------------------------------|

End point description:

A Neuropathy Questionnaire measures participant's symptom experience over past 7 days using 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. Neuropathy Questionnaire was used to determine chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For first, participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For second, CIPN was assigned if participant recorded a score greater than 1 ("a little bit"). Only those participants with data available at indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 7 years, 7 months and 4 days

| <b>End point values</b>     | non-gBRCA Niraparib  | non-gBRCA Placebo    |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed | 185 <sup>[109]</sup> | 105 <sup>[110]</sup> |  |  |
| Units: Participants         |                      |                      |  |  |
| Feet, 0-Not at all          | 57                   | 32                   |  |  |
| Feet, 1-A little bit        | 45                   | 12                   |  |  |
| Feet, 2-Somewhat            | 23                   | 16                   |  |  |
| Feet, 3-Quite a bit         | 19                   | 16                   |  |  |
| Feet, 4-Very much           | 5                    | 8                    |  |  |
| Hands, 0-Not at all         | 88                   | 48                   |  |  |
| Hands, 1-A little bit       | 35                   | 15                   |  |  |
| Hands, 2-Somewhat           | 13                   | 9                    |  |  |

|                      |   |    |  |  |
|----------------------|---|----|--|--|
| Hands, 3-Quite a bit | 7 | 10 |  |  |
| Hands, 4-Very much   | 3 | 1  |  |  |

Notes:

[109] - Intent-to-treat population

[110] - Intent-to-treat population

## Statistical analyses

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 290                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | = 0.2798                                |
| Method                                  | Pearson's Chi-squared test              |

|                                         |                                         |
|-----------------------------------------|-----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                  |
| Comparison groups                       | non-gBRCA Niraparib v non-gBRCA Placebo |
| Number of subjects included in analysis | 290                                     |
| Analysis specification                  | Pre-specified                           |
| Analysis type                           | superiority                             |
| P-value                                 | = 0.0259                                |
| Method                                  | Pearson's Chi-squared test              |

## Secondary: Number of participants with non-serious adverse events (AEs) and serious AEs (SAEs)

|                 |                                                                                                      |
|-----------------|------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with non-serious adverse events (AEs) and serious AEs (SAEs) <sup>[111]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. Safety Population consisted of all participants who ingested any amount of study drug.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 7 years, 7 months and 6 days

Notes:

[111] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | gBRCA Niraparib      | gBRCA Placebo       | Non-gBRCA Niraparib  | Non-gBRCA Placebo    |
|-----------------------------|----------------------|---------------------|----------------------|----------------------|
| Subject group type          | Reporting group      | Reporting group     | Reporting group      | Reporting group      |
| Number of subjects analysed | 136 <sup>[112]</sup> | 65 <sup>[113]</sup> | 231 <sup>[114]</sup> | 114 <sup>[115]</sup> |
| Units: Participants         |                      |                     |                      |                      |
| Non-serious AEs             | 136                  | 62                  | 231                  | 110                  |
| SAEs                        | 51                   | 9                   | 76                   | 20                   |

Notes:

[112] - Safety Population

[113] - Safety Population

[114] - Safety Population

[115] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with non-serious AEs and SAEs in FE sub-study

|                 |                                                                      |
|-----------------|----------------------------------------------------------------------|
| End point title | Number of participants with non-serious AEs and SAEs in FE sub-study |
|-----------------|----------------------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 2 years 3 months and 11 days

| End point values            | FE Niraparib Fasted  | FE Niraparib Fed     |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed | 16 <sup>[116]</sup>  | 16 <sup>[117]</sup>  |  |  |
| Units: Participants         |                      |                      |  |  |
| Non-serious AEs             | 4                    | 6                    |  |  |
| SAEs                        | 1                    | 0                    |  |  |

Notes:

[116] - Safety Population

[117] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with non-serious AEs and SAEs in QTc sub-study

|                 |                                                                                        |
|-----------------|----------------------------------------------------------------------------------------|
| End point title | Number of participants with non-serious AEs and SAEs in QTc sub-study <sup>[118]</sup> |
|-----------------|----------------------------------------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence that occurs in a participants or clinical investigation

participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 5 years 10 months and 22 days

Notes:

[118] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

|                             |                             |  |  |  |
|-----------------------------|-----------------------------|--|--|--|
| <b>End point values</b>     | QTc sub-study:<br>Niraparib |  |  |  |
| Subject group type          | Reporting group             |  |  |  |
| Number of subjects analysed | 26 <sup>[119]</sup>         |  |  |  |
| Units: Participants         |                             |  |  |  |
| Non-serious AEs             | 24                          |  |  |  |
| SAEs                        | 12                          |  |  |  |

Notes:

[119] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0-infinity]) following administration of Niraparib (FE sub-study)

|                 |                                                                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC[0-infinity]) following administration of Niraparib (FE sub-study) |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib. Pharmacokinetic population consisted of all participants who received at least one dose of study drug, with sufficient data available to calculate parameters. Only those participants with data available at the specified time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-dose and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

|                                      |                         |                       |  |  |
|--------------------------------------|-------------------------|-----------------------|--|--|
| <b>End point values</b>              | FE Niraparib<br>Fasted  | FE Niraparib<br>Fed   |  |  |
| Subject group type                   | Subject analysis set    | Subject analysis set  |  |  |
| Number of subjects analysed          | 15 <sup>[120]</sup>     | 14 <sup>[121]</sup>   |  |  |
| Units: Nanograms*hour per milliliter |                         |                       |  |  |
| arithmetic mean (standard deviation) | 29016.1 (±<br>18405.23) | 31194 (±<br>16894.88) |  |  |

Notes:

[120] - Pharmacokinetic population

[121] - Pharmacokinetic population

## Statistical analyses

|                                         |                                        |
|-----------------------------------------|----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                 |
| Comparison groups                       | FE Niraparib Fasted v FE Niraparib Fed |
| Number of subjects included in analysis | 29                                     |
| Analysis specification                  | Pre-specified                          |
| Analysis type                           |                                        |
| Parameter estimate                      | Ratio of Least square mean             |
| Point estimate                          | 1.1                                    |
| Confidence interval                     |                                        |
| level                                   | 90 %                                   |
| sides                                   | 2-sided                                |
| lower limit                             | 0.997                                  |
| upper limit                             | 1.216                                  |

## Secondary: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-last]) following administration of Niraparib (FE sub-study)

|                 |                                                                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-last]) following administration of Niraparib (FE sub-study) |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Blood samples were collected at indicated time points to analyze the AUC(0-last) of niraparib. Only those participants with data available at the indicated time points were analyzed.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose

|                                      |                      |                      |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| <b>End point values</b>              | FE Niraparib Fasted  | FE Niraparib Fed     |  |  |
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 16 <sup>[122]</sup>  | 15                   |  |  |
| Units: Nanograms*hour per milliliter |                      |                      |  |  |
| arithmetic mean (standard deviation) | 28638.1 (± 17911.86) | 27186.4 (± 14111.37) |  |  |

Notes:

[122] - Pharmacokinetic population

## Statistical analyses

|                                         |                                        |
|-----------------------------------------|----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                 |
| Comparison groups                       | FE Niraparib Fasted v FE Niraparib Fed |
| Number of subjects included in analysis | 31                                     |
| Analysis specification                  | Pre-specified                          |
| Analysis type                           |                                        |
| Parameter estimate                      | Ratio of Least square mean             |
| Point estimate                          | 1.068                                  |
| Confidence interval                     |                                        |
| level                                   | 90 %                                   |
| sides                                   | 2-sided                                |
| lower limit                             | 0.978                                  |
| upper limit                             | 1.166                                  |

### Secondary: Maximum observed plasma concentration (Cmax) following administration of Niraparib (FE sub-study)

|                        |                                                                                                                                                                                                                  |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Maximum observed plasma concentration (Cmax) following administration of Niraparib (FE sub-study)                                                                                                                |
| End point description: | Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib. Only those participants with data available at the indicated time points were analyzed. |
| End point type         | Secondary                                                                                                                                                                                                        |
| End point timeframe:   | Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose                                                                                                                          |

| End point values                     | FE Niraparib Fasted  | FE Niraparib Fed     |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 16 <sup>[123]</sup>  | 15                   |  |  |
| Units: Nanograms per milliliter      |                      |                      |  |  |
| arithmetic mean (standard deviation) | 803.7 (± 403.35)     | 582.1 (± 228.57)     |  |  |

Notes:

[123] - Pharmacokinetic population

### Statistical analyses

|                                         |                                        |
|-----------------------------------------|----------------------------------------|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                 |
| Comparison groups                       | FE Niraparib Fasted v FE Niraparib Fed |
| Number of subjects included in analysis | 31                                     |
| Analysis specification                  | Pre-specified                          |
| Analysis type                           |                                        |
| Parameter estimate                      | Ratio of Least square mean             |
| Point estimate                          | 0.785                                  |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 90 %    |
| sides               | 2-sided |
| lower limit         | 0.695   |
| upper limit         | 0.886   |

### Secondary: Time to reach maximum (tmax) following administration of Niraparib (FE sub-study)

|                                                                                                                                                                                                           |                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                           | Time to reach maximum (tmax) following administration of Niraparib (FE sub-study) |
| End point description:<br>Blood samples were collected at indicated time points to analyze the tmax of niraparib. Only those participants with data available at the indicated time points were analyzed. |                                                                                   |
| End point type                                                                                                                                                                                            | Secondary                                                                         |
| End point timeframe:<br>Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose                                                                                           |                                                                                   |

| End point values              | FE Niraparib Fasted  | FE Niraparib Fed     |  |  |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type            | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed   | 16 <sup>[124]</sup>  | 15                   |  |  |
| Units: Hour                   |                      |                      |  |  |
| median (full range (min-max)) | 3.1 (1.7 to 6.1)     | 6.1 (1.2 to 23)      |  |  |

Notes:

[124] - Pharmacokinetic population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Terminal elimination half-life (t1/2) following administration of Niraparib (FE sub-study)

|                                                                                                                                                                                                           |                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                           | Terminal elimination half-life (t1/2) following administration of Niraparib (FE sub-study) |
| End point description:<br>Blood samples were collected at indicated time points to analyze the t1/2 of niraparib. Only those participants with data available at the indicated time points were analyzed. |                                                                                            |
| End point type                                                                                                                                                                                            | Secondary                                                                                  |
| End point timeframe:<br>Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose                                                                                           |                                                                                            |

| End point values                     | FE Niraparib Fasted  | FE Niraparib Fed     |  |  |
|--------------------------------------|----------------------|----------------------|--|--|
| Subject group type                   | Subject analysis set | Subject analysis set |  |  |
| Number of subjects analysed          | 16 <sup>[125]</sup>  | 14 <sup>[126]</sup>  |  |  |
| Units: Hour                          |                      |                      |  |  |
| arithmetic mean (standard deviation) | 50.5 (± 17.87)       | 47.9 (± 17.54)       |  |  |

Notes:

[125] - Pharmacokinetic population

[126] - Pharmacokinetic population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with maximum post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) greater than pre-specified thresholds

|                 |                                                                                                                                                               |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of participants with maximum post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) greater than pre-specified thresholds <sup>[127]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval >450 and ≤ 480 milliseconds (msec) and >500 msec.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Baseline (Cycle 1 Day 1, each cycle was of 28 days)

Notes:

[127] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting on a subset of the arms that are contained in the baseline period

| End point values            | QTc sub-study: Niraparib |  |  |  |
|-----------------------------|--------------------------|--|--|--|
| Subject group type          | Reporting group          |  |  |  |
| Number of subjects analysed | 26 <sup>[128]</sup>      |  |  |  |
| Units: Participants         |                          |  |  |  |
| >450 msec                   | 2                        |  |  |  |
| >480 msec                   | 0                        |  |  |  |
| >500 msec                   | 0                        |  |  |  |

Notes:

[128] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, non-serious AEs (non-SAEs) and SAEs were collected up to 7 years, 7 months and 6 days

Adverse event reporting additional description:

Safety Population was used to assess SAEs and non-SAEs, which comprised of all participants who ingested any amount of study drug.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 23.0 |
|--------------------|------|

### Reporting groups

|                       |                 |
|-----------------------|-----------------|
| Reporting group title | gBRCA Niraparib |
|-----------------------|-----------------|

Reporting group description:

Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.

|                       |               |
|-----------------------|---------------|
| Reporting group title | gBRCA Placebo |
|-----------------------|---------------|

Reporting group description:

Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | Non-gBRCA Niraparib |
|-----------------------|---------------------|

Reporting group description:

Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Non-gBRCA Placebo |
|-----------------------|-------------------|

Reporting group description:

Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | FE Niraparib Fasted |
|-----------------------|---------------------|

Reporting group description:

Participants received Niraparib 300 mg in fasted condition

|                       |                  |
|-----------------------|------------------|
| Reporting group title | FE Niraparib Fed |
|-----------------------|------------------|

Reporting group description:

Participants received Niraparib 300 mg in fed condition

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | QTc sub-study: Niraparib |
|-----------------------|--------------------------|

Reporting group description:

Participants received Niraparib 300 mg once daily orally.

| Serious adverse events                                              | gBRCA Niraparib   | gBRCA Placebo   | Non-gBRCA Niraparib |
|---------------------------------------------------------------------|-------------------|-----------------|---------------------|
| Total subjects affected by serious adverse events                   |                   |                 |                     |
| subjects affected / exposed                                         | 51 / 136 (37.50%) | 9 / 65 (13.85%) | 76 / 231 (32.90%)   |
| number of deaths (all causes)                                       | 72                | 29              | 146                 |
| number of deaths resulting from adverse events                      |                   |                 |                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                   |                 |                     |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| Acute myeloid leukaemia                         |                 |                |                 |
| subjects affected / exposed                     | 6 / 136 (4.41%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 6 / 6           | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 2 / 2           | 0 / 1          | 0 / 0           |
| Myelodysplastic syndrome                        |                 |                |                 |
| subjects affected / exposed                     | 5 / 136 (3.68%) | 1 / 65 (1.54%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 5 / 5           | 0 / 1          | 2 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 2 / 2           |
| Metastases to central nervous system            |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Metastases to peritoneum                        |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Acute erythroid leukaemia                       |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 1 / 1          | 0 / 0           |
| Intraductal proliferative breast lesion         |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Squamous cell carcinoma                         |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Undifferentiated sarcoma                        |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Breast cancer                                   |                 |                |                 |

|                                                      |                 |                |                 |
|------------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                          | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Ovarian cancer recurrent                             |                 |                |                 |
| subjects affected / exposed                          | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Vascular disorders                                   |                 |                |                 |
| Hypertensive crisis                                  |                 |                |                 |
| subjects affected / exposed                          | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all      | 1 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Peripheral artery thrombosis                         |                 |                |                 |
| subjects affected / exposed                          | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| General disorders and administration site conditions |                 |                |                 |
| Pyrexia                                              |                 |                |                 |
| subjects affected / exposed                          | 2 / 136 (1.47%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all      | 0 / 2           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Mucosal inflammation                                 |                 |                |                 |
| subjects affected / exposed                          | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all      | 1 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Non-cardiac chest pain                               |                 |                |                 |
| subjects affected / exposed                          | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |
| Disease progression                                  |                 |                |                 |
| subjects affected / exposed                          | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 2           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0           |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| Pain                                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| General physical health deterioration           |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Immune system disorders                         |                 |                |                 |
| Anaphylactoid reaction                          |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Reproductive system and breast disorders        |                 |                |                 |
| Breast disorder                                 |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                |                 |
| Pleural effusion                                |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 1 / 65 (1.54%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1          | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Acute pulmonary oedema                          |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Dyspnoea                                        |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pulmonary embolism                              |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Respiratory disorder                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Asthma                                          |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pleuritic pain                                  |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pneumonitis                                     |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Psychiatric disorders                           |                 |                |                 |
| Anxiety                                         |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Behaviour disorder                              |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Suicide attempt                                 |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Hallucination                                   |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Depression                                      |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Product issues                                  |                 |                |                 |
| Thrombosis in device                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Investigations                                  |                 |                |                 |
| Neutrophil count decreased                      |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Troponin increased                              |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Platelet count decreased                        |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 2 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Transaminases increased                         |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                |                 |
| Hip fracture                                    |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| Incisional hernia                               |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Post procedural discomfort                      |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Transfusion reaction                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Procedural complication                         |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Product use complaint                           |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Cardiac disorders                               |                 |                |                 |
| Cardiac failure                                 |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Tachycardia                                     |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Angina pectoris                                 |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Coronary artery stenosis                        |                 |                |                 |

|                                                 |                   |                |                  |
|-------------------------------------------------|-------------------|----------------|------------------|
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%) | 1 / 231 (0.43%)  |
| occurrences causally related to treatment / all | 0 / 0             | 0 / 0          | 0 / 1            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Pericardial effusion                            |                   |                |                  |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%) | 1 / 231 (0.43%)  |
| occurrences causally related to treatment / all | 0 / 0             | 0 / 0          | 0 / 1            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Sinus tachycardia                               |                   |                |                  |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%) | 1 / 231 (0.43%)  |
| occurrences causally related to treatment / all | 0 / 0             | 0 / 0          | 0 / 1            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Nervous system disorders                        |                   |                |                  |
| Depressed level of consciousness                |                   |                |                  |
| subjects affected / exposed                     | 1 / 136 (0.74%)   | 0 / 65 (0.00%) | 0 / 231 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 1             | 0 / 0          | 0 / 0            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Syncope                                         |                   |                |                  |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%) | 1 / 231 (0.43%)  |
| occurrences causally related to treatment / all | 0 / 0             | 0 / 0          | 0 / 1            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Transient ischaemic attack                      |                   |                |                  |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%) | 1 / 231 (0.43%)  |
| occurrences causally related to treatment / all | 0 / 0             | 0 / 0          | 1 / 1            |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Blood and lymphatic system disorders            |                   |                |                  |
| Thrombocytopenia                                |                   |                |                  |
| subjects affected / exposed                     | 18 / 136 (13.24%) | 0 / 65 (0.00%) | 23 / 231 (9.96%) |
| occurrences causally related to treatment / all | 38 / 38           | 0 / 0          | 36 / 36          |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Anaemia                                         |                   |                |                  |
| subjects affected / exposed                     | 4 / 136 (2.94%)   | 0 / 65 (0.00%) | 13 / 231 (5.63%) |
| occurrences causally related to treatment / all | 6 / 6             | 0 / 0          | 15 / 15          |
| deaths causally related to treatment / all      | 0 / 0             | 0 / 0          | 0 / 0            |
| Neutropenia                                     |                   |                |                  |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pancytopenia                                    |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 3 / 3           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Febrile neutropenia                             |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Gastrointestinal disorders                      |                 |                |                 |
| Small intestinal obstruction                    |                 |                |                 |
| subjects affected / exposed                     | 3 / 136 (2.21%) | 0 / 65 (0.00%) | 6 / 231 (2.60%) |
| occurrences causally related to treatment / all | 0 / 3           | 0 / 0          | 0 / 7           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Ascites                                         |                 |                |                 |
| subjects affected / exposed                     | 2 / 136 (1.47%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Nausea                                          |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 2 / 65 (3.08%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 2          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Abdominal pain                                  |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Abdominal pain upper                            |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Constipation                                    |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 3 / 231 (1.30%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 3           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Ileus paralytic                                 |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Intestinal obstruction                          |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pancreatitis                                    |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Subileus                                        |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Abdominal hernia                                |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Abdominal pain lower                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Gastrooesophageal reflux disease                |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Impaired gastric emptying                       |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Malignant gastrointestinal obstruction          |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Obstruction gastric                             |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Vomiting                                        |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 2 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Oesophagitis                                    |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Ileus                                           |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Abdominal distension                            |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Diarrhoea                                       |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Hepatobiliary disorders                         |                 |                |                 |
| Cholecystitis                                   |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Cholestasis                                     |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Hepatic failure                                 |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Renal and urinary disorders                     |                 |                |                 |
| Acute kidney injury                             |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Nephrolithiasis                                 |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Hydronephrosis                                  |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 1 / 65 (1.54%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Urinary tract obstruction                       |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Renal failure                                   |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| Arthropathy                                     |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Infections and infestations                     |                 |                |                 |
| Urinary tract infection                         |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 1 / 65 (1.54%) | 2 / 231 (0.87%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1          | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Erysipelas                                      |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Bronchitis                                      |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Infection                                       |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Pneumonia                                       |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 3 / 231 (1.30%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 1 / 4           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 1           |
| Pyelonephritis                                  |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Sepsis                                          |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 1 / 1           |
| Tracheobronchitis                               |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Upper respiratory tract infection               |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Wound infection                                 |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 1 / 231 (0.43%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Device related infection                        |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Empyema                                         |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Influenza                                       |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                |                 |
| Hyperglycaemia                                  |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Hypomagnesaemia                                 |                 |                |                 |
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Type 2 diabetes mellitus                        |                 |                |                 |

|                                                 |                 |                |                 |
|-------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 136 (0.74%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |
| Decreased appetite                              |                 |                |                 |
| subjects affected / exposed                     | 0 / 136 (0.00%) | 0 / 65 (0.00%) | 0 / 231 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0           |

| <b>Serious adverse events</b>                                       | Non-gBRCA Placebo | FE Niraparib Fasted | FE Niraparib Fed |
|---------------------------------------------------------------------|-------------------|---------------------|------------------|
| Total subjects affected by serious adverse events                   |                   |                     |                  |
| subjects affected / exposed                                         | 20 / 114 (17.54%) | 1 / 16 (6.25%)      | 0 / 16 (0.00%)   |
| number of deaths (all causes)                                       | 68                | 0                   | 0                |
| number of deaths resulting from adverse events                      |                   |                     |                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                   |                     |                  |
| Acute myeloid leukaemia                                             |                   |                     |                  |
| subjects affected / exposed                                         | 0 / 114 (0.00%)   | 0 / 16 (0.00%)      | 0 / 16 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0             | 0 / 0               | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0             | 0 / 0               | 0 / 0            |
| Myelodysplastic syndrome                                            |                   |                     |                  |
| subjects affected / exposed                                         | 0 / 114 (0.00%)   | 0 / 16 (0.00%)      | 0 / 16 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0             | 0 / 0               | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0             | 0 / 0               | 0 / 0            |
| Metastases to central nervous system                                |                   |                     |                  |
| subjects affected / exposed                                         | 1 / 114 (0.88%)   | 0 / 16 (0.00%)      | 0 / 16 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 1             | 0 / 0               | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0             | 0 / 0               | 0 / 0            |
| Metastases to peritoneum                                            |                   |                     |                  |
| subjects affected / exposed                                         | 0 / 114 (0.00%)   | 0 / 16 (0.00%)      | 0 / 16 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0             | 0 / 0               | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0             | 0 / 0               | 0 / 0            |
| Acute erythroid leukaemia                                           |                   |                     |                  |
| subjects affected / exposed                                         | 0 / 114 (0.00%)   | 0 / 16 (0.00%)      | 0 / 16 (0.00%)   |
| occurrences causally related to treatment / all                     | 0 / 0             | 0 / 0               | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0             | 0 / 0               | 0 / 0            |

|                                                      |                 |                |                |
|------------------------------------------------------|-----------------|----------------|----------------|
| Intraductal proliferative breast lesion              |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                              |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Undifferentiated sarcoma                             |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Breast cancer                                        |                 |                |                |
| subjects affected / exposed                          | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Ovarian cancer recurrent                             |                 |                |                |
| subjects affected / exposed                          | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Vascular disorders                                   |                 |                |                |
| Hypertensive crisis                                  |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| Peripheral artery thrombosis                         |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions |                 |                |                |
| Pyrexia                                              |                 |                |                |
| subjects affected / exposed                          | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0          | 0 / 0          |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| Mucosal inflammation                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Non-cardiac chest pain                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Disease progression                             |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pain                                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| General physical health deterioration           |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Immune system disorders                         |                 |                |                |
| Anaphylactoid reaction                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                 |                |                |
| Breast disorder                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                 |                |                |
| Pleural effusion                                |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Acute pulmonary oedema                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Dyspnoea                                        |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pulmonary embolism                              |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Respiratory disorder                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Asthma                                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pleuritic pain                                  |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pneumonitis                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Psychiatric disorders                           |                 |                |                |
| Anxiety                                         |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Behaviour disorder                              |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Suicide attempt                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hallucination                                   |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Depression                                      |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Product issues                                  |                 |                |                |
| Thrombosis in device                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Investigations                                  |                 |                |                |
| Neutrophil count decreased                      |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Troponin increased                              |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Platelet count decreased                        |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Transaminases increased                         |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications  |                 |                |                |
| Hip fracture                                    |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Incisional hernia                               |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Post procedural discomfort                      |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Transfusion reaction                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Procedural complication                         |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Product use complaint                           |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| Cardiac failure                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Tachycardia                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Angina pectoris                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Coronary artery stenosis                        |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pericardial effusion                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Sinus tachycardia                               |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                 |                |                |
| Depressed level of consciousness                |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Syncope                                         |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Blood and lymphatic system disorders</b>     |                 |                |                |
| Thrombocytopenia                                |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Anaemia                                         |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Neutropenia                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pancytopenia                                    |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Febrile neutropenia                             |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Gastrointestinal disorders</b>               |                 |                |                |
| Small intestinal obstruction                    |                 |                |                |
| subjects affected / exposed                     | 4 / 114 (3.51%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 5           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Ascites                                         |                 |                |                |
| subjects affected / exposed                     | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Nausea                                          |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Abdominal pain                                  |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Abdominal pain upper                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Constipation                                    |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Ileus paralytic                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Intestinal obstruction                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pancreatitis                                    |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Subileus                                        |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Abdominal hernia                                |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Abdominal pain lower                            |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Gastrooesophageal reflux disease                |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Impaired gastric emptying                       |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Malignant gastrointestinal obstruction          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Obstruction gastric                             |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Vomiting                                        |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Oesophagitis                                    |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Ileus                                           |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Abdominal distension                            |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Diarrhoea                                       |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                 |                |                |
| Cholecystitis                                   |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Cholestasis                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hepatic failure                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Renal and urinary disorders                     |                 |                |                |
| Acute kidney injury                             |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Nephrolithiasis                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hydronephrosis                                  |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Urinary tract obstruction                       |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Renal failure                                   |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                 |                |                |
| Arthropathy                                     |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                 |                |                |
| Urinary tract infection                         |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 1 / 16 (6.25%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Erysipelas                                      |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Bronchitis                                      |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Infection                                       |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| Pneumonia                                       |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Pyelonephritis                                  |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Sepsis                                          |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Tracheobronchitis                               |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Upper respiratory tract infection               |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Wound infection                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Device related infection                        |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Empyema                                         |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Influenza                                       |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Metabolism and nutrition disorders</b>       |                 |                |                |
| Hyperglycaemia                                  |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hypomagnesaemia                                 |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Type 2 diabetes mellitus                        |                 |                |                |
| subjects affected / exposed                     | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Decreased appetite                              |                 |                |                |
| subjects affected / exposed                     | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |

|                                                                     |                             |  |  |
|---------------------------------------------------------------------|-----------------------------|--|--|
| <b>Serious adverse events</b>                                       | QTc sub-study:<br>Niraparib |  |  |
| Total subjects affected by serious adverse events                   |                             |  |  |
| subjects affected / exposed                                         | 12 / 26 (46.15%)            |  |  |
| number of deaths (all causes)                                       | 5                           |  |  |
| number of deaths resulting from adverse events                      |                             |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                             |  |  |
| Acute myeloid leukaemia                                             |                             |  |  |
| subjects affected / exposed                                         | 0 / 26 (0.00%)              |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                       |  |  |
| deaths causally related to treatment / all                          | 0 / 0                       |  |  |
| Myelodysplastic syndrome                                            |                             |  |  |

|                                                 |                |  |  |  |
|-------------------------------------------------|----------------|--|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Metastases to central nervous system            |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Metastases to peritoneum                        |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Acute erythroid leukaemia                       |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Intraductal proliferative breast lesion         |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Squamous cell carcinoma                         |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Undifferentiated sarcoma                        |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Breast cancer                                   |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Ovarian cancer recurrent                        |                |  |  |  |

|                                                      |                |  |  |
|------------------------------------------------------|----------------|--|--|
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Vascular disorders                                   |                |  |  |
| Hypertensive crisis                                  |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Peripheral artery thrombosis                         |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| General disorders and administration site conditions |                |  |  |
| Pyrexia                                              |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Mucosal inflammation                                 |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Non-cardiac chest pain                               |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Disease progression                                  |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Pain                                                 |                |  |  |
| subjects affected / exposed                          | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |

|                                                                      |                |  |  |
|----------------------------------------------------------------------|----------------|--|--|
| General physical health deterioration<br>subjects affected / exposed | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Immune system disorders                                              |                |  |  |
| Anaphylactoid reaction<br>subjects affected / exposed                | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Reproductive system and breast<br>disorders                          |                |  |  |
| Breast disorder<br>subjects affected / exposed                       | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Respiratory, thoracic and mediastinal<br>disorders                   |                |  |  |
| Pleural effusion<br>subjects affected / exposed                      | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Acute pulmonary oedema<br>subjects affected / exposed                | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Dyspnoea<br>subjects affected / exposed                              | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Pulmonary embolism<br>subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences causally related to<br>treatment / all                   | 0 / 0          |  |  |
| deaths causally related to<br>treatment / all                        | 0 / 0          |  |  |
| Respiratory disorder                                                 |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Asthma                                          |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pleuritic pain                                  |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pneumonitis                                     |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Psychiatric disorders                           |                |  |  |
| Anxiety                                         |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Behaviour disorder                              |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Suicide attempt                                 |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hallucination                                   |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Depression                                      |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Product issues                                  |                |  |  |
| Thrombosis in device                            |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Investigations                                  |                |  |  |
| Neutrophil count decreased                      |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Troponin increased                              |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Platelet count decreased                        |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Transaminases increased                         |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Injury, poisoning and procedural complications  |                |  |  |
| Hip fracture                                    |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Incisional hernia                               |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

|                                                 |                |  |  |  |
|-------------------------------------------------|----------------|--|--|--|
| Post procedural discomfort                      |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Transfusion reaction                            |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Procedural complication                         |                |  |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Product use complaint                           |                |  |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Cardiac disorders                               |                |  |  |  |
| Cardiac failure                                 |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Tachycardia                                     |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Angina pectoris                                 |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Coronary artery stenosis                        |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Pericardial effusion                            |                |  |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Sinus tachycardia                               |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Nervous system disorders                        |                 |  |  |
| Depressed level of consciousness                |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Syncope                                         |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Transient ischaemic attack                      |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Blood and lymphatic system disorders            |                 |  |  |
| Thrombocytopenia                                |                 |  |  |
| subjects affected / exposed                     | 3 / 26 (11.54%) |  |  |
| occurrences causally related to treatment / all | 9 / 9           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Anaemia                                         |                 |  |  |
| subjects affected / exposed                     | 2 / 26 (7.69%)  |  |  |
| occurrences causally related to treatment / all | 2 / 2           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Neutropenia                                     |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Pancytopenia                                    |                 |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Febrile neutropenia                             |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Gastrointestinal disorders                      |                |  |  |
| Small intestinal obstruction                    |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Ascites                                         |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Nausea                                          |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Abdominal pain                                  |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Abdominal pain upper                            |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Constipation                                    |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Ileus paralytic                                 |                |  |  |

|                                                 |                |  |  |  |
|-------------------------------------------------|----------------|--|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Intestinal obstruction                          |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Pancreatitis                                    |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Subileus                                        |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Abdominal hernia                                |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Abdominal pain lower                            |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Gastrooesophageal reflux disease                |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Impaired gastric emptying                       |                |  |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |  |
| Malignant gastrointestinal obstruction          |                |  |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Obstruction gastric                             |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Vomiting                                        |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Oesophagitis                                    |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 1 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Ileus                                           |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Abdominal distension                            |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Diarrhoea                                       |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hepatobiliary disorders                         |                |  |  |
| Cholecystitis                                   |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Cholestasis                                     |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hepatic failure                                 |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Renal and urinary disorders                     |                |  |  |
| Acute kidney injury                             |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Nephrolithiasis                                 |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hydronephrosis                                  |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Urinary tract obstruction                       |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Renal failure                                   |                |  |  |
| subjects affected / exposed                     | 1 / 26 (3.85%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Arthropathy                                     |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

|                                                                                                                                                                                        |                                  |  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--|--|
| Infections and infestations<br>Urinary tract infection<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all | 1 / 26 (3.85%)<br>0 / 1<br>0 / 0 |  |  |
| Erysipelas<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                             | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Bronchitis<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                             | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Infection<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                              | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Pneumonia<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                              | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Pyelonephritis<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                         | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Sepsis<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                                 | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Tracheobronchitis<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                      | 0 / 26 (0.00%)<br>0 / 0<br>0 / 0 |  |  |
| Upper respiratory tract infection                                                                                                                                                      |                                  |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Wound infection                                 |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Device related infection                        |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Empyema                                         |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Influenza                                       |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Metabolism and nutrition disorders              |                |  |  |
| Hyperglycaemia                                  |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hypomagnesaemia                                 |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Type 2 diabetes mellitus                        |                |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Decreased appetite                              |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | gBRCA Niraparib     | gBRCA Placebo    | Non-gBRCA Niraparib |
|-------------------------------------------------------|---------------------|------------------|---------------------|
| Total subjects affected by non-serious adverse events |                     |                  |                     |
| subjects affected / exposed                           | 136 / 136 (100.00%) | 62 / 65 (95.38%) | 231 / 231 (100.00%) |
| Vascular disorders                                    |                     |                  |                     |
| Deep vein thrombosis                                  |                     |                  |                     |
| subjects affected / exposed                           | 0 / 136 (0.00%)     | 0 / 65 (0.00%)   | 0 / 231 (0.00%)     |
| occurrences (all)                                     | 0                   | 0                | 0                   |
| Hypertension                                          |                     |                  |                     |
| subjects affected / exposed                           | 38 / 136 (27.94%)   | 5 / 65 (7.69%)   | 46 / 231 (19.91%)   |
| occurrences (all)                                     | 123                 | 6                | 207                 |
| Hot flush                                             |                     |                  |                     |
| subjects affected / exposed                           | 10 / 136 (7.35%)    | 3 / 65 (4.62%)   | 24 / 231 (10.39%)   |
| occurrences (all)                                     | 11                  | 3                | 43                  |
| General disorders and administration site conditions  |                     |                  |                     |
| Fatigue                                               |                     |                  |                     |
| subjects affected / exposed                           | 66 / 136 (48.53%)   | 19 / 65 (29.23%) | 110 / 231 (47.62%)  |
| occurrences (all)                                     | 134                 | 37               | 189                 |
| Pain                                                  |                     |                  |                     |
| subjects affected / exposed                           | 0 / 136 (0.00%)     | 0 / 65 (0.00%)   | 0 / 231 (0.00%)     |
| occurrences (all)                                     | 0                   | 0                | 0                   |
| Catheter site pain                                    |                     |                  |                     |
| subjects affected / exposed                           | 0 / 136 (0.00%)     | 0 / 65 (0.00%)   | 0 / 231 (0.00%)     |
| occurrences (all)                                     | 0                   | 0                | 0                   |
| Asthenia                                              |                     |                  |                     |
| subjects affected / exposed                           | 27 / 136 (19.85%)   | 3 / 65 (4.62%)   | 36 / 231 (15.58%)   |
| occurrences (all)                                     | 75                  | 3                | 81                  |
| Oedema peripheral                                     |                     |                  |                     |
| subjects affected / exposed                           | 12 / 136 (8.82%)    | 2 / 65 (3.08%)   | 15 / 231 (6.49%)    |
| occurrences (all)                                     | 15                  | 3                | 23                  |

|                                                 |                   |                 |                   |
|-------------------------------------------------|-------------------|-----------------|-------------------|
| Pyrexia                                         |                   |                 |                   |
| subjects affected / exposed                     | 11 / 136 (8.09%)  | 4 / 65 (6.15%)  | 16 / 231 (6.93%)  |
| occurrences (all)                               | 17                | 5               | 23                |
| Influenza like illness                          |                   |                 |                   |
| subjects affected / exposed                     | 8 / 136 (5.88%)   | 1 / 65 (1.54%)  | 0 / 231 (0.00%)   |
| occurrences (all)                               | 11                | 1               | 0                 |
| Mucosal inflammation                            |                   |                 |                   |
| subjects affected / exposed                     | 7 / 136 (5.15%)   | 1 / 65 (1.54%)  | 19 / 231 (8.23%)  |
| occurrences (all)                               | 9                 | 1               | 23                |
| Respiratory, thoracic and mediastinal disorders |                   |                 |                   |
| Cough                                           |                   |                 |                   |
| subjects affected / exposed                     | 26 / 136 (19.12%) | 2 / 65 (3.08%)  | 42 / 231 (18.18%) |
| occurrences (all)                               | 36                | 4               | 60                |
| Dyspnoea                                        |                   |                 |                   |
| subjects affected / exposed                     | 23 / 136 (16.91%) | 3 / 65 (4.62%)  | 49 / 231 (21.21%) |
| occurrences (all)                               | 34                | 4               | 62                |
| Dysphonia                                       |                   |                 |                   |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%)  | 0 / 231 (0.00%)   |
| occurrences (all)                               | 0                 | 0               | 0                 |
| Nasal congestion                                |                   |                 |                   |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%)  | 0 / 231 (0.00%)   |
| occurrences (all)                               | 0                 | 0               | 0                 |
| Oropharyngeal pain                              |                   |                 |                   |
| subjects affected / exposed                     | 11 / 136 (8.09%)  | 2 / 65 (3.08%)  | 16 / 231 (6.93%)  |
| occurrences (all)                               | 19                | 2               | 21                |
| Epistaxis                                       |                   |                 |                   |
| subjects affected / exposed                     | 7 / 136 (5.15%)   | 0 / 65 (0.00%)  | 12 / 231 (5.19%)  |
| occurrences (all)                               | 9                 | 0               | 15                |
| Psychiatric disorders                           |                   |                 |                   |
| Insomnia                                        |                   |                 |                   |
| subjects affected / exposed                     | 26 / 136 (19.12%) | 6 / 65 (9.23%)  | 67 / 231 (29.00%) |
| occurrences (all)                               | 36                | 7               | 88                |
| Anxiety                                         |                   |                 |                   |
| subjects affected / exposed                     | 12 / 136 (8.82%)  | 7 / 65 (10.77%) | 21 / 231 (9.09%)  |
| occurrences (all)                               | 27                | 11              | 27                |
| Depression                                      |                   |                 |                   |

|                                                                                          |                         |                      |                          |
|------------------------------------------------------------------------------------------|-------------------------|----------------------|--------------------------|
| subjects affected / exposed<br>occurrences (all)                                         | 9 / 136 (6.62%)<br>14   | 2 / 65 (3.08%)<br>3  | 14 / 231 (6.06%)<br>21   |
| Investigations                                                                           |                         |                      |                          |
| Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all)           | 11 / 136 (8.09%)<br>29  | 3 / 65 (4.62%)<br>4  | 15 / 231 (6.49%)<br>32   |
| Neutrophil count decreased<br>subjects affected / exposed<br>occurrences (all)           | 23 / 136 (16.91%)<br>64 | 3 / 65 (4.62%)<br>5  | 31 / 231 (13.42%)<br>79  |
| Platelet count decreased<br>subjects affected / exposed<br>occurrences (all)             | 34 / 136 (25.00%)<br>85 | 1 / 65 (1.54%)<br>1  | 45 / 231 (19.48%)<br>132 |
| White blood cell count decreased<br>subjects affected / exposed<br>occurrences (all)     | 20 / 136 (14.71%)<br>42 | 5 / 65 (7.69%)<br>14 | 22 / 231 (9.52%)<br>64   |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all)                     | 9 / 136 (6.62%)<br>15   | 0 / 65 (0.00%)<br>0  | 0 / 231 (0.00%)<br>0     |
| Gamma-glutamyltransferase increased<br>subjects affected / exposed<br>occurrences (all)  | 7 / 136 (5.15%)<br>17   | 3 / 65 (4.62%)<br>3  | 20 / 231 (8.66%)<br>48   |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)   | 7 / 136 (5.15%)<br>10   | 0 / 65 (0.00%)<br>0  | 13 / 231 (5.63%)<br>21   |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all) | 7 / 136 (5.15%)<br>15   | 0 / 65 (0.00%)<br>0  | 15 / 231 (6.49%)<br>27   |
| Blood alkaline phosphatase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 136 (0.00%)<br>0    | 0 / 65 (0.00%)<br>0  | 13 / 231 (5.63%)<br>19   |
| Injury, poisoning and procedural complications                                           |                         |                      |                          |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                            | 10 / 136 (7.35%)<br>12  | 0 / 65 (0.00%)<br>0  | 0 / 231 (0.00%)<br>0     |
| Fall                                                                                     |                         |                      |                          |

|                                                  |                       |                     |                      |
|--------------------------------------------------|-----------------------|---------------------|----------------------|
| subjects affected / exposed<br>occurrences (all) | 7 / 136 (5.15%)<br>10 | 0 / 65 (0.00%)<br>0 | 0 / 231 (0.00%)<br>0 |
| Cardiac disorders                                |                       |                     |                      |
| Atrial fibrillation                              |                       |                     |                      |
| subjects affected / exposed                      | 0 / 136 (0.00%)       | 0 / 65 (0.00%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 0                     | 0                   | 0                    |
| Palpitations                                     |                       |                     |                      |
| subjects affected / exposed                      | 14 / 136 (10.29%)     | 1 / 65 (1.54%)      | 27 / 231 (11.69%)    |
| occurrences (all)                                | 19                    | 1                   | 35                   |
| Tachycardia                                      |                       |                     |                      |
| subjects affected / exposed                      | 11 / 136 (8.09%)      | 1 / 65 (1.54%)      | 14 / 231 (6.06%)     |
| occurrences (all)                                | 13                    | 1                   | 20                   |
| Nervous system disorders                         |                       |                     |                      |
| Amnesia                                          |                       |                     |                      |
| subjects affected / exposed                      | 0 / 136 (0.00%)       | 0 / 65 (0.00%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 0                     | 0                   | 0                    |
| Dizziness                                        |                       |                     |                      |
| subjects affected / exposed                      | 26 / 136 (19.12%)     | 7 / 65 (10.77%)     | 43 / 231 (18.61%)    |
| occurrences (all)                                | 39                    | 14                  | 53                   |
| Headache                                         |                       |                     |                      |
| subjects affected / exposed                      | 52 / 136 (38.24%)     | 7 / 65 (10.77%)     | 52 / 231 (22.51%)    |
| occurrences (all)                                | 76                    | 12                  | 97                   |
| Neuropathy peripheral                            |                       |                     |                      |
| subjects affected / exposed                      | 13 / 136 (9.56%)      | 4 / 65 (6.15%)      | 14 / 231 (6.06%)     |
| occurrences (all)                                | 17                    | 4                   | 19                   |
| Dysgeusia                                        |                       |                     |                      |
| subjects affected / exposed                      | 12 / 136 (8.82%)      | 1 / 65 (1.54%)      | 14 / 231 (6.06%)     |
| occurrences (all)                                | 13                    | 1                   | 18                   |
| Paraesthesia                                     |                       |                     |                      |
| subjects affected / exposed                      | 11 / 136 (8.09%)      | 1 / 65 (1.54%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 31                    | 1                   | 0                    |
| Peripheral sensory neuropathy                    |                       |                     |                      |
| subjects affected / exposed                      | 7 / 136 (5.15%)       | 0 / 65 (0.00%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 7                     | 0                   | 0                    |
| Blood and lymphatic system disorders             |                       |                     |                      |

|                             |                   |                  |                    |
|-----------------------------|-------------------|------------------|--------------------|
| Anaemia                     |                   |                  |                    |
| subjects affected / exposed | 74 / 136 (54.41%) | 5 / 65 (7.69%)   | 111 / 231 (48.05%) |
| occurrences (all)           | 259               | 5                | 328                |
| Neutropenia                 |                   |                  |                    |
| subjects affected / exposed | 24 / 136 (17.65%) | 3 / 65 (4.62%)   | 42 / 231 (18.18%)  |
| occurrences (all)           | 77                | 7                | 128                |
| Thrombocytopenia            |                   |                  |                    |
| subjects affected / exposed | 73 / 136 (53.68%) | 2 / 65 (3.08%)   | 93 / 231 (40.26%)  |
| occurrences (all)           | 226               | 3                | 256                |
| Leukopenia                  |                   |                  |                    |
| subjects affected / exposed | 11 / 136 (8.09%)  | 4 / 65 (6.15%)   | 17 / 231 (7.36%)   |
| occurrences (all)           | 38                | 6                | 52                 |
| Eye disorders               |                   |                  |                    |
| Dry eye                     |                   |                  |                    |
| subjects affected / exposed | 0 / 136 (0.00%)   | 0 / 65 (0.00%)   | 0 / 231 (0.00%)    |
| occurrences (all)           | 0                 | 0                | 0                  |
| Gastrointestinal disorders  |                   |                  |                    |
| Abdominal pain              |                   |                  |                    |
| subjects affected / exposed | 34 / 136 (25.00%) | 17 / 65 (26.15%) | 63 / 231 (27.27%)  |
| occurrences (all)           | 50                | 24               | 93                 |
| Abdominal pain lower        |                   |                  |                    |
| subjects affected / exposed | 0 / 136 (0.00%)   | 0 / 65 (0.00%)   | 0 / 231 (0.00%)    |
| occurrences (all)           | 0                 | 0                | 0                  |
| Ascites                     |                   |                  |                    |
| subjects affected / exposed | 0 / 136 (0.00%)   | 0 / 65 (0.00%)   | 0 / 231 (0.00%)    |
| occurrences (all)           | 0                 | 0                | 0                  |
| Constipation                |                   |                  |                    |
| subjects affected / exposed | 56 / 136 (41.18%) | 12 / 65 (18.46%) | 96 / 231 (41.56%)  |
| occurrences (all)           | 105               | 14               | 163                |
| Diarrhoea                   |                   |                  |                    |
| subjects affected / exposed | 40 / 136 (29.41%) | 15 / 65 (23.08%) | 44 / 231 (19.05%)  |
| occurrences (all)           | 71                | 28               | 76                 |
| Flatulence                  |                   |                  |                    |
| subjects affected / exposed | 7 / 136 (5.15%)   | 3 / 65 (4.62%)   | 12 / 231 (5.19%)   |
| occurrences (all)           | 9                 | 3                | 17                 |
| Nausea                      |                   |                  |                    |

|                                        |                    |                  |                    |
|----------------------------------------|--------------------|------------------|--------------------|
| subjects affected / exposed            | 106 / 136 (77.94%) | 23 / 65 (35.38%) | 168 / 231 (72.73%) |
| occurrences (all)                      | 205                | 46               | 304                |
| Stomatitis                             |                    |                  |                    |
| subjects affected / exposed            | 5 / 136 (3.68%)    | 4 / 65 (6.15%)   | 11 / 231 (4.76%)   |
| occurrences (all)                      | 5                  | 4                | 18                 |
| Vomiting                               |                    |                  |                    |
| subjects affected / exposed            | 57 / 136 (41.91%)  | 10 / 65 (15.38%) | 74 / 231 (32.03%)  |
| occurrences (all)                      | 96                 | 13               | 126                |
| Abdominal pain upper                   |                    |                  |                    |
| subjects affected / exposed            | 17 / 136 (12.50%)  | 9 / 65 (13.85%)  | 24 / 231 (10.39%)  |
| occurrences (all)                      | 26                 | 12               | 36                 |
| Abdominal distension                   |                    |                  |                    |
| subjects affected / exposed            | 4 / 136 (2.94%)    | 6 / 65 (9.23%)   | 23 / 231 (9.96%)   |
| occurrences (all)                      | 6                  | 7                | 29                 |
| Dyspepsia                              |                    |                  |                    |
| subjects affected / exposed            | 23 / 136 (16.91%)  | 10 / 65 (15.38%) | 22 / 231 (9.52%)   |
| occurrences (all)                      | 37                 | 11               | 25                 |
| Dry mouth                              |                    |                  |                    |
| subjects affected / exposed            | 19 / 136 (13.97%)  | 2 / 65 (3.08%)   | 19 / 231 (8.23%)   |
| occurrences (all)                      | 38                 | 5                | 27                 |
| Haemorrhoids                           |                    |                  |                    |
| subjects affected / exposed            | 7 / 136 (5.15%)    | 2 / 65 (3.08%)   | 0 / 231 (0.00%)    |
| occurrences (all)                      | 7                  | 2                | 0                  |
| Gastrooesophageal reflux disease       |                    |                  |                    |
| subjects affected / exposed            | 0 / 136 (0.00%)    | 0 / 65 (0.00%)   | 22 / 231 (9.52%)   |
| occurrences (all)                      | 0                  | 0                | 25                 |
| Skin and subcutaneous tissue disorders |                    |                  |                    |
| Photosensitivity reaction              |                    |                  |                    |
| subjects affected / exposed            | 11 / 136 (8.09%)   | 0 / 65 (0.00%)   | 25 / 231 (10.82%)  |
| occurrences (all)                      | 13                 | 0                | 37                 |
| Rash                                   |                    |                  |                    |
| subjects affected / exposed            | 14 / 136 (10.29%)  | 1 / 65 (1.54%)   | 16 / 231 (6.93%)   |
| occurrences (all)                      | 16                 | 1                | 20                 |
| Alopecia                               |                    |                  |                    |
| subjects affected / exposed            | 15 / 136 (11.03%)  | 6 / 65 (9.23%)   | 20 / 231 (8.66%)   |
| occurrences (all)                      | 17                 | 6                | 21                 |

|                                                 |                   |                  |                   |
|-------------------------------------------------|-------------------|------------------|-------------------|
| Pruritus                                        |                   |                  |                   |
| subjects affected / exposed                     | 12 / 136 (8.82%)  | 3 / 65 (4.62%)   | 5 / 231 (2.16%)   |
| occurrences (all)                               | 13                | 3                | 5                 |
| Petechiae                                       |                   |                  |                   |
| subjects affected / exposed                     | 9 / 136 (6.62%)   | 0 / 65 (0.00%)   | 0 / 231 (0.00%)   |
| occurrences (all)                               | 10                | 0                | 0                 |
| Dry skin                                        |                   |                  |                   |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%)   | 18 / 231 (7.79%)  |
| occurrences (all)                               | 0                 | 0                | 30                |
| Renal and urinary disorders                     |                   |                  |                   |
| Dysuria                                         |                   |                  |                   |
| subjects affected / exposed                     | 7 / 136 (5.15%)   | 1 / 65 (1.54%)   | 0 / 231 (0.00%)   |
| occurrences (all)                               | 11                | 1                | 0                 |
| Musculoskeletal and connective tissue disorders |                   |                  |                   |
| Joint swelling                                  |                   |                  |                   |
| subjects affected / exposed                     | 0 / 136 (0.00%)   | 0 / 65 (0.00%)   | 0 / 231 (0.00%)   |
| occurrences (all)                               | 0                 | 0                | 0                 |
| Arthralgia                                      |                   |                  |                   |
| subjects affected / exposed                     | 29 / 136 (21.32%) | 10 / 65 (15.38%) | 27 / 231 (11.69%) |
| occurrences (all)                               | 44                | 11               | 40                |
| Back pain                                       |                   |                  |                   |
| subjects affected / exposed                     | 29 / 136 (21.32%) | 9 / 65 (13.85%)  | 33 / 231 (14.29%) |
| occurrences (all)                               | 40                | 9                | 38                |
| Pain in extremity                               |                   |                  |                   |
| subjects affected / exposed                     | 19 / 136 (13.97%) | 4 / 65 (6.15%)   | 16 / 231 (6.93%)  |
| occurrences (all)                               | 27                | 4                | 19                |
| Muscle spasms                                   |                   |                  |                   |
| subjects affected / exposed                     | 16 / 136 (11.76%) | 2 / 65 (3.08%)   | 14 / 231 (6.06%)  |
| occurrences (all)                               | 24                | 2                | 15                |
| Myalgia                                         |                   |                  |                   |
| subjects affected / exposed                     | 15 / 136 (11.03%) | 6 / 65 (9.23%)   | 21 / 231 (9.09%)  |
| occurrences (all)                               | 18                | 7                | 24                |
| Musculoskeletal pain                            |                   |                  |                   |
| subjects affected / exposed                     | 11 / 136 (8.09%)  | 2 / 65 (3.08%)   | 12 / 231 (5.19%)  |
| occurrences (all)                               | 14                | 2                | 23                |
| Musculoskeletal chest pain                      |                   |                  |                   |

|                                                  |                      |                     |                      |
|--------------------------------------------------|----------------------|---------------------|----------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 136 (0.00%)<br>0 | 0 / 65 (0.00%)<br>0 | 8 / 231 (3.46%)<br>9 |
| <b>Infections and infestations</b>               |                      |                     |                      |
| Urinary tract infection                          |                      |                     |                      |
| subjects affected / exposed                      | 20 / 136 (14.71%)    | 6 / 65 (9.23%)      | 26 / 231 (11.26%)    |
| occurrences (all)                                | 25                   | 11                  | 40                   |
| Nasopharyngitis                                  |                      |                     |                      |
| subjects affected / exposed                      | 21 / 136 (15.44%)    | 4 / 65 (6.15%)      | 29 / 231 (12.55%)    |
| occurrences (all)                                | 33                   | 7                   | 40                   |
| Upper respiratory tract infection                |                      |                     |                      |
| subjects affected / exposed                      | 15 / 136 (11.03%)    | 3 / 65 (4.62%)      | 14 / 231 (6.06%)     |
| occurrences (all)                                | 18                   | 5                   | 18                   |
| Sinusitis                                        |                      |                     |                      |
| subjects affected / exposed                      | 10 / 136 (7.35%)     | 1 / 65 (1.54%)      | 15 / 231 (6.49%)     |
| occurrences (all)                                | 13                   | 1                   | 19                   |
| Bronchitis                                       |                      |                     |                      |
| subjects affected / exposed                      | 6 / 136 (4.41%)      | 4 / 65 (6.15%)      | 15 / 231 (6.49%)     |
| occurrences (all)                                | 8                    | 4                   | 19                   |
| <b>Metabolism and nutrition disorders</b>        |                      |                     |                      |
| Decreased appetite                               |                      |                     |                      |
| subjects affected / exposed                      | 30 / 136 (22.06%)    | 9 / 65 (13.85%)     | 67 / 231 (29.00%)    |
| occurrences (all)                                | 49                   | 12                  | 94                   |
| Dehydration                                      |                      |                     |                      |
| subjects affected / exposed                      | 0 / 136 (0.00%)      | 0 / 65 (0.00%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 0                    | 0                   | 0                    |
| Hyperglycaemia                                   |                      |                     |                      |
| subjects affected / exposed                      | 7 / 136 (5.15%)      | 5 / 65 (7.69%)      | 0 / 231 (0.00%)      |
| occurrences (all)                                | 8                    | 10                  | 0                    |
| Hypokalaemia                                     |                      |                     |                      |
| subjects affected / exposed                      | 11 / 136 (8.09%)     | 5 / 65 (7.69%)      | 15 / 231 (6.49%)     |
| occurrences (all)                                | 14                   | 10                  | 26                   |
| Hypomagnesaemia                                  |                      |                     |                      |
| subjects affected / exposed                      | 15 / 136 (11.03%)    | 8 / 65 (12.31%)     | 18 / 231 (7.79%)     |
| occurrences (all)                                | 40                   | 18                  | 28                   |

|                                        |                   |                     |                  |
|----------------------------------------|-------------------|---------------------|------------------|
| <b>Non-serious adverse events</b>      | Non-gBRCA Placebo | FE Niraparib Fasted | FE Niraparib Fed |
| Total subjects affected by non-serious |                   |                     |                  |

|                                                      |                    |                 |                 |
|------------------------------------------------------|--------------------|-----------------|-----------------|
| adverse events                                       |                    |                 |                 |
| subjects affected / exposed                          | 110 / 114 (96.49%) | 4 / 16 (25.00%) | 6 / 16 (37.50%) |
| Vascular disorders                                   |                    |                 |                 |
| Deep vein thrombosis                                 |                    |                 |                 |
| subjects affected / exposed                          | 0 / 114 (0.00%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 0                  | 0               | 0               |
| Hypertension                                         |                    |                 |                 |
| subjects affected / exposed                          | 4 / 114 (3.51%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 5                  | 0               | 0               |
| Hot flush                                            |                    |                 |                 |
| subjects affected / exposed                          | 6 / 114 (5.26%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 8                  | 0               | 0               |
| General disorders and administration site conditions |                    |                 |                 |
| Fatigue                                              |                    |                 |                 |
| subjects affected / exposed                          | 38 / 114 (33.33%)  | 0 / 16 (0.00%)  | 1 / 16 (6.25%)  |
| occurrences (all)                                    | 53                 | 0               | 1               |
| Pain                                                 |                    |                 |                 |
| subjects affected / exposed                          | 0 / 114 (0.00%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 0                  | 0               | 0               |
| Catheter site pain                                   |                    |                 |                 |
| subjects affected / exposed                          | 0 / 114 (0.00%)    | 1 / 16 (6.25%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 0                  | 1               | 0               |
| Asthenia                                             |                    |                 |                 |
| subjects affected / exposed                          | 13 / 114 (11.40%)  | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 17                 | 0               | 0               |
| Oedema peripheral                                    |                    |                 |                 |
| subjects affected / exposed                          | 6 / 114 (5.26%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 10                 | 0               | 0               |
| Pyrexia                                              |                    |                 |                 |
| subjects affected / exposed                          | 7 / 114 (6.14%)    | 0 / 16 (0.00%)  | 1 / 16 (6.25%)  |
| occurrences (all)                                    | 8                  | 0               | 1               |
| Influenza like illness                               |                    |                 |                 |
| subjects affected / exposed                          | 0 / 114 (0.00%)    | 0 / 16 (0.00%)  | 0 / 16 (0.00%)  |
| occurrences (all)                                    | 0                  | 0               | 0               |
| Mucosal inflammation                                 |                    |                 |                 |

|                                                  |                      |                     |                     |
|--------------------------------------------------|----------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 2 / 114 (1.75%)<br>2 | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders  |                      |                     |                     |
| Cough                                            |                      |                     |                     |
| subjects affected / exposed                      | 8 / 114 (7.02%)      | 1 / 16 (6.25%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 9                    | 1                   | 0                   |
| Dyspnoea                                         |                      |                     |                     |
| subjects affected / exposed                      | 12 / 114 (10.53%)    | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 14                   | 0                   | 0                   |
| Dysphonia                                        |                      |                     |                     |
| subjects affected / exposed                      | 0 / 114 (0.00%)      | 0 / 16 (0.00%)      | 1 / 16 (6.25%)      |
| occurrences (all)                                | 0                    | 0                   | 1                   |
| Nasal congestion                                 |                      |                     |                     |
| subjects affected / exposed                      | 0 / 114 (0.00%)      | 0 / 16 (0.00%)      | 1 / 16 (6.25%)      |
| occurrences (all)                                | 0                    | 0                   | 1                   |
| Oropharyngeal pain                               |                      |                     |                     |
| subjects affected / exposed                      | 3 / 114 (2.63%)      | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 4                    | 0                   | 0                   |
| Epistaxis                                        |                      |                     |                     |
| subjects affected / exposed                      | 4 / 114 (3.51%)      | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 4                    | 0                   | 0                   |
| Psychiatric disorders                            |                      |                     |                     |
| Insomnia                                         |                      |                     |                     |
| subjects affected / exposed                      | 10 / 114 (8.77%)     | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 11                   | 0                   | 0                   |
| Anxiety                                          |                      |                     |                     |
| subjects affected / exposed                      | 5 / 114 (4.39%)      | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 5                    | 0                   | 0                   |
| Depression                                       |                      |                     |                     |
| subjects affected / exposed                      | 1 / 114 (0.88%)      | 0 / 16 (0.00%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 1                    | 0                   | 0                   |
| Investigations                                   |                      |                     |                     |
| Blood creatinine increased                       |                      |                     |                     |
| subjects affected / exposed                      | 3 / 114 (2.63%)      | 1 / 16 (6.25%)      | 0 / 16 (0.00%)      |
| occurrences (all)                                | 3                    | 1                   | 0                   |
| Neutrophil count decreased                       |                      |                     |                     |

|                                                |                 |                |                |
|------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                    | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0              |
| Platelet count decreased                       |                 |                |                |
| subjects affected / exposed                    | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0              |
| White blood cell count decreased               |                 |                |                |
| subjects affected / exposed                    | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0              |
| Weight decreased                               |                 |                |                |
| subjects affected / exposed                    | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0              |
| Gamma-glutamyltransferase increased            |                 |                |                |
| subjects affected / exposed                    | 5 / 114 (4.39%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 9               | 0              | 0              |
| Alanine aminotransferase increased             |                 |                |                |
| subjects affected / exposed                    | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 4               | 0              | 0              |
| Aspartate aminotransferase increased           |                 |                |                |
| subjects affected / exposed                    | 2 / 114 (1.75%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0              |
| Blood alkaline phosphatase increased           |                 |                |                |
| subjects affected / exposed                    | 1 / 114 (0.88%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0              |
| Injury, poisoning and procedural complications |                 |                |                |
| Contusion                                      |                 |                |                |
| subjects affected / exposed                    | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0              |
| Fall                                           |                 |                |                |
| subjects affected / exposed                    | 0 / 114 (0.00%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0              |
| Cardiac disorders                              |                 |                |                |
| Atrial fibrillation                            |                 |                |                |
| subjects affected / exposed                    | 0 / 114 (0.00%) | 1 / 16 (6.25%) | 0 / 16 (0.00%) |
| occurrences (all)                              | 0               | 1              | 0              |
| Palpitations                                   |                 |                |                |

|                                      |                   |                |                |
|--------------------------------------|-------------------|----------------|----------------|
| subjects affected / exposed          | 4 / 114 (3.51%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 4                 | 0              | 0              |
| Tachycardia                          |                   |                |                |
| subjects affected / exposed          | 1 / 114 (0.88%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 1                 | 0              | 0              |
| Nervous system disorders             |                   |                |                |
| Amnesia                              |                   |                |                |
| subjects affected / exposed          | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 0                 | 0              | 0              |
| Dizziness                            |                   |                |                |
| subjects affected / exposed          | 9 / 114 (7.89%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 12                | 0              | 0              |
| Headache                             |                   |                |                |
| subjects affected / exposed          | 14 / 114 (12.28%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 21                | 0              | 0              |
| Neuropathy peripheral                |                   |                |                |
| subjects affected / exposed          | 8 / 114 (7.02%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 9                 | 0              | 0              |
| Dysgeusia                            |                   |                |                |
| subjects affected / exposed          | 3 / 114 (2.63%)   | 0 / 16 (0.00%) | 1 / 16 (6.25%) |
| occurrences (all)                    | 3                 | 0              | 1              |
| Paraesthesia                         |                   |                |                |
| subjects affected / exposed          | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 0                 | 0              | 0              |
| Peripheral sensory neuropathy        |                   |                |                |
| subjects affected / exposed          | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 0                 | 0              | 0              |
| Blood and lymphatic system disorders |                   |                |                |
| Anaemia                              |                   |                |                |
| subjects affected / exposed          | 7 / 114 (6.14%)   | 1 / 16 (6.25%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 11                | 1              | 0              |
| Neutropenia                          |                   |                |                |
| subjects affected / exposed          | 3 / 114 (2.63%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                    | 14                | 0              | 0              |
| Thrombocytopenia                     |                   |                |                |

|                             |                   |                |                |
|-----------------------------|-------------------|----------------|----------------|
| subjects affected / exposed | 4 / 114 (3.51%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 4                 | 0              | 0              |
| Leukopenia                  |                   |                |                |
| subjects affected / exposed | 5 / 114 (4.39%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 17                | 0              | 0              |
| Eye disorders               |                   |                |                |
| Dry eye                     |                   |                |                |
| subjects affected / exposed | 0 / 114 (0.00%)   | 1 / 16 (6.25%) | 0 / 16 (0.00%) |
| occurrences (all)           | 0                 | 1              | 0              |
| Gastrointestinal disorders  |                   |                |                |
| Abdominal pain              |                   |                |                |
| subjects affected / exposed | 39 / 114 (34.21%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 50                | 0              | 0              |
| Abdominal pain lower        |                   |                |                |
| subjects affected / exposed | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 0                 | 0              | 0              |
| Ascites                     |                   |                |                |
| subjects affected / exposed | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 0                 | 0              | 0              |
| Constipation                |                   |                |                |
| subjects affected / exposed | 23 / 114 (20.18%) | 0 / 16 (0.00%) | 1 / 16 (6.25%) |
| occurrences (all)           | 30                | 0              | 1              |
| Diarrhoea                   |                   |                |                |
| subjects affected / exposed | 23 / 114 (20.18%) | 1 / 16 (6.25%) | 0 / 16 (0.00%) |
| occurrences (all)           | 34                | 2              | 0              |
| Flatulence                  |                   |                |                |
| subjects affected / exposed | 9 / 114 (7.89%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 10                | 0              | 0              |
| Nausea                      |                   |                |                |
| subjects affected / exposed | 41 / 114 (35.96%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 59                | 0              | 0              |
| Stomatitis                  |                   |                |                |
| subjects affected / exposed | 7 / 114 (6.14%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)           | 11                | 0              | 0              |
| Vomiting                    |                   |                |                |

|                                        |                   |                |                |
|----------------------------------------|-------------------|----------------|----------------|
| subjects affected / exposed            | 21 / 114 (18.42%) | 0 / 16 (0.00%) | 1 / 16 (6.25%) |
| occurrences (all)                      | 31                | 0              | 1              |
| Abdominal pain upper                   |                   |                |                |
| subjects affected / exposed            | 9 / 114 (7.89%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 17                | 0              | 0              |
| Abdominal distension                   |                   |                |                |
| subjects affected / exposed            | 15 / 114 (13.16%) | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 17                | 0              | 0              |
| Dyspepsia                              |                   |                |                |
| subjects affected / exposed            | 9 / 114 (7.89%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 10                | 0              | 0              |
| Dry mouth                              |                   |                |                |
| subjects affected / exposed            | 5 / 114 (4.39%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 6                 | 0              | 0              |
| Haemorrhoids                           |                   |                |                |
| subjects affected / exposed            | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 0                 | 0              | 0              |
| Gastrooesophageal reflux disease       |                   |                |                |
| subjects affected / exposed            | 4 / 114 (3.51%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 4                 | 0              | 0              |
| Skin and subcutaneous tissue disorders |                   |                |                |
| Photosensitivity reaction              |                   |                |                |
| subjects affected / exposed            | 1 / 114 (0.88%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 1                 | 0              | 0              |
| Rash                                   |                   |                |                |
| subjects affected / exposed            | 5 / 114 (4.39%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 5                 | 0              | 0              |
| Alopecia                               |                   |                |                |
| subjects affected / exposed            | 8 / 114 (7.02%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 9                 | 0              | 0              |
| Pruritus                               |                   |                |                |
| subjects affected / exposed            | 8 / 114 (7.02%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 8                 | 0              | 0              |
| Petechiae                              |                   |                |                |
| subjects affected / exposed            | 0 / 114 (0.00%)   | 0 / 16 (0.00%) | 0 / 16 (0.00%) |
| occurrences (all)                      | 0                 | 0              | 0              |

|                                                                                                                       |                         |                     |                     |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------|---------------------|
| Dry skin<br>subjects affected / exposed<br>occurrences (all)                                                          | 5 / 114 (4.39%)<br>7    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 114 (0.00%)<br>0    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders<br>Joint swelling<br>subjects affected / exposed<br>occurrences (all) | 0 / 114 (0.00%)<br>0    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                                                        | 14 / 114 (12.28%)<br>20 | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                                                         | 16 / 114 (14.04%)<br>38 | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)                                                 | 13 / 114 (11.40%)<br>14 | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)                                                     | 5 / 114 (4.39%)<br>5    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)                                                           | 12 / 114 (10.53%)<br>13 | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Musculoskeletal pain<br>subjects affected / exposed<br>occurrences (all)                                              | 3 / 114 (2.63%)<br>3    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Musculoskeletal chest pain<br>subjects affected / exposed<br>occurrences (all)                                        | 7 / 114 (6.14%)<br>11   | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Infections and infestations<br>Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)            | 5 / 114 (4.39%)<br>5    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |

|                                                                                       |                         |                     |                     |
|---------------------------------------------------------------------------------------|-------------------------|---------------------|---------------------|
| Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)                   | 11 / 114 (9.65%)<br>17  | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 4 / 114 (3.51%)<br>5    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Sinusitis<br>subjects affected / exposed<br>occurrences (all)                         | 2 / 114 (1.75%)<br>2    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)                        | 2 / 114 (1.75%)<br>2    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                                    |                         |                     |                     |
| Decreased appetite<br>subjects affected / exposed<br>occurrences (all)                | 18 / 114 (15.79%)<br>22 | 1 / 16 (6.25%)<br>1 | 0 / 16 (0.00%)<br>0 |
| Dehydration<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 114 (0.00%)<br>0    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 114 (0.00%)<br>0    | 0 / 16 (0.00%)<br>0 | 0 / 16 (0.00%)<br>0 |
| Hypokalaemia<br>subjects affected / exposed<br>occurrences (all)                      | 4 / 114 (3.51%)<br>5    | 1 / 16 (6.25%)<br>1 | 1 / 16 (6.25%)<br>1 |
| Hypomagnesaemia<br>subjects affected / exposed<br>occurrences (all)                   | 6 / 114 (5.26%)<br>14   | 1 / 16 (6.25%)<br>1 | 0 / 16 (0.00%)<br>0 |

|                                                                                      |                             |  |  |
|--------------------------------------------------------------------------------------|-----------------------------|--|--|
| <b>Non-serious adverse events</b>                                                    | QTc sub-study:<br>Niraparib |  |  |
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 24 / 26 (92.31%)            |  |  |
| Vascular disorders                                                                   |                             |  |  |
| Deep vein thrombosis<br>subjects affected / exposed<br>occurrences (all)             | 2 / 26 (7.69%)<br>2         |  |  |
| Hypertension                                                                         |                             |  |  |

|                                                                            |                        |  |  |
|----------------------------------------------------------------------------|------------------------|--|--|
| subjects affected / exposed<br>occurrences (all)                           | 4 / 26 (15.38%)<br>4   |  |  |
| Hot flush<br>subjects affected / exposed<br>occurrences (all)              | 0 / 26 (0.00%)<br>0    |  |  |
| General disorders and administration<br>site conditions                    |                        |  |  |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                | 13 / 26 (50.00%)<br>20 |  |  |
| Pain<br>subjects affected / exposed<br>occurrences (all)                   | 2 / 26 (7.69%)<br>2    |  |  |
| Catheter site pain<br>subjects affected / exposed<br>occurrences (all)     | 0 / 26 (0.00%)<br>0    |  |  |
| Asthenia<br>subjects affected / exposed<br>occurrences (all)               | 0 / 26 (0.00%)<br>0    |  |  |
| Oedema peripheral<br>subjects affected / exposed<br>occurrences (all)      | 5 / 26 (19.23%)<br>5   |  |  |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                | 0 / 26 (0.00%)<br>0    |  |  |
| Influenza like illness<br>subjects affected / exposed<br>occurrences (all) | 0 / 26 (0.00%)<br>0    |  |  |
| Mucosal inflammation<br>subjects affected / exposed<br>occurrences (all)   | 0 / 26 (0.00%)<br>0    |  |  |
| Respiratory, thoracic and mediastinal<br>disorders                         |                        |  |  |
| Cough<br>subjects affected / exposed<br>occurrences (all)                  | 4 / 26 (15.38%)<br>6   |  |  |
| Dyspnoea                                                                   |                        |  |  |

|                                  |                 |  |  |
|----------------------------------|-----------------|--|--|
| subjects affected / exposed      | 4 / 26 (15.38%) |  |  |
| occurrences (all)                | 4               |  |  |
| Dysphonia                        |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Nasal congestion                 |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Oropharyngeal pain               |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Epistaxis                        |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Psychiatric disorders            |                 |  |  |
| Insomnia                         |                 |  |  |
| subjects affected / exposed      | 3 / 26 (11.54%) |  |  |
| occurrences (all)                | 3               |  |  |
| Anxiety                          |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Depression                       |                 |  |  |
| subjects affected / exposed      | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                | 0               |  |  |
| Investigations                   |                 |  |  |
| Blood creatinine increased       |                 |  |  |
| subjects affected / exposed      | 4 / 26 (15.38%) |  |  |
| occurrences (all)                | 6               |  |  |
| Neutrophil count decreased       |                 |  |  |
| subjects affected / exposed      | 4 / 26 (15.38%) |  |  |
| occurrences (all)                | 6               |  |  |
| Platelet count decreased         |                 |  |  |
| subjects affected / exposed      | 3 / 26 (11.54%) |  |  |
| occurrences (all)                | 8               |  |  |
| White blood cell count decreased |                 |  |  |

|                                                |                |  |  |
|------------------------------------------------|----------------|--|--|
| subjects affected / exposed                    | 2 / 26 (7.69%) |  |  |
| occurrences (all)                              | 5              |  |  |
| Weight decreased                               |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Gamma-glutamyltransferase increased            |                |  |  |
| subjects affected / exposed                    | 2 / 26 (7.69%) |  |  |
| occurrences (all)                              | 2              |  |  |
| Alanine aminotransferase increased             |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Aspartate aminotransferase increased           |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Blood alkaline phosphatase increased           |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Injury, poisoning and procedural complications |                |  |  |
| Contusion                                      |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Fall                                           |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Cardiac disorders                              |                |  |  |
| Atrial fibrillation                            |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Palpitations                                   |                |  |  |
| subjects affected / exposed                    | 0 / 26 (0.00%) |  |  |
| occurrences (all)                              | 0              |  |  |
| Tachycardia                                    |                |  |  |
| subjects affected / exposed                    | 2 / 26 (7.69%) |  |  |
| occurrences (all)                              | 2              |  |  |
| Nervous system disorders                       |                |  |  |

|                                      |                  |  |  |
|--------------------------------------|------------------|--|--|
| Amnesia                              |                  |  |  |
| subjects affected / exposed          | 3 / 26 (11.54%)  |  |  |
| occurrences (all)                    | 3                |  |  |
| Dizziness                            |                  |  |  |
| subjects affected / exposed          | 4 / 26 (15.38%)  |  |  |
| occurrences (all)                    | 5                |  |  |
| Headache                             |                  |  |  |
| subjects affected / exposed          | 5 / 26 (19.23%)  |  |  |
| occurrences (all)                    | 7                |  |  |
| Neuropathy peripheral                |                  |  |  |
| subjects affected / exposed          | 2 / 26 (7.69%)   |  |  |
| occurrences (all)                    | 2                |  |  |
| Dysgeusia                            |                  |  |  |
| subjects affected / exposed          | 0 / 26 (0.00%)   |  |  |
| occurrences (all)                    | 0                |  |  |
| Paraesthesia                         |                  |  |  |
| subjects affected / exposed          | 0 / 26 (0.00%)   |  |  |
| occurrences (all)                    | 0                |  |  |
| Peripheral sensory neuropathy        |                  |  |  |
| subjects affected / exposed          | 0 / 26 (0.00%)   |  |  |
| occurrences (all)                    | 0                |  |  |
| Blood and lymphatic system disorders |                  |  |  |
| Anaemia                              |                  |  |  |
| subjects affected / exposed          | 12 / 26 (46.15%) |  |  |
| occurrences (all)                    | 23               |  |  |
| Neutropenia                          |                  |  |  |
| subjects affected / exposed          | 10 / 26 (38.46%) |  |  |
| occurrences (all)                    | 19               |  |  |
| Thrombocytopenia                     |                  |  |  |
| subjects affected / exposed          | 13 / 26 (50.00%) |  |  |
| occurrences (all)                    | 36               |  |  |
| Leukopenia                           |                  |  |  |
| subjects affected / exposed          | 0 / 26 (0.00%)   |  |  |
| occurrences (all)                    | 0                |  |  |
| Eye disorders                        |                  |  |  |

|                             |                  |  |  |
|-----------------------------|------------------|--|--|
| Dry eye                     |                  |  |  |
| subjects affected / exposed | 0 / 26 (0.00%)   |  |  |
| occurrences (all)           | 0                |  |  |
| Gastrointestinal disorders  |                  |  |  |
| Abdominal pain              |                  |  |  |
| subjects affected / exposed | 7 / 26 (26.92%)  |  |  |
| occurrences (all)           | 8                |  |  |
| Abdominal pain lower        |                  |  |  |
| subjects affected / exposed | 2 / 26 (7.69%)   |  |  |
| occurrences (all)           | 2                |  |  |
| Ascites                     |                  |  |  |
| subjects affected / exposed | 2 / 26 (7.69%)   |  |  |
| occurrences (all)           | 2                |  |  |
| Constipation                |                  |  |  |
| subjects affected / exposed | 9 / 26 (34.62%)  |  |  |
| occurrences (all)           | 12               |  |  |
| Diarrhoea                   |                  |  |  |
| subjects affected / exposed | 2 / 26 (7.69%)   |  |  |
| occurrences (all)           | 2                |  |  |
| Flatulence                  |                  |  |  |
| subjects affected / exposed | 2 / 26 (7.69%)   |  |  |
| occurrences (all)           | 2                |  |  |
| Nausea                      |                  |  |  |
| subjects affected / exposed | 13 / 26 (50.00%) |  |  |
| occurrences (all)           | 16               |  |  |
| Stomatitis                  |                  |  |  |
| subjects affected / exposed | 2 / 26 (7.69%)   |  |  |
| occurrences (all)           | 2                |  |  |
| Vomiting                    |                  |  |  |
| subjects affected / exposed | 10 / 26 (38.46%) |  |  |
| occurrences (all)           | 11               |  |  |
| Abdominal pain upper        |                  |  |  |
| subjects affected / exposed | 0 / 26 (0.00%)   |  |  |
| occurrences (all)           | 0                |  |  |
| Abdominal distension        |                  |  |  |

|                                        |                |  |  |
|----------------------------------------|----------------|--|--|
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dyspepsia                              |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dry mouth                              |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Haemorrhoids                           |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Gastrooesophageal reflux disease       |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Skin and subcutaneous tissue disorders |                |  |  |
| Photosensitivity reaction              |                |  |  |
| subjects affected / exposed            | 2 / 26 (7.69%) |  |  |
| occurrences (all)                      | 2              |  |  |
| Rash                                   |                |  |  |
| subjects affected / exposed            | 2 / 26 (7.69%) |  |  |
| occurrences (all)                      | 2              |  |  |
| Alopecia                               |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Pruritus                               |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Petechiae                              |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dry skin                               |                |  |  |
| subjects affected / exposed            | 0 / 26 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Renal and urinary disorders            |                |  |  |
| Dysuria                                |                |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Joint swelling                                  |                 |  |  |
| subjects affected / exposed                     | 3 / 26 (11.54%) |  |  |
| occurrences (all)                               | 3               |  |  |
| Arthralgia                                      |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Back pain                                       |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Pain in extremity                               |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Muscle spasms                                   |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Myalgia                                         |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Musculoskeletal pain                            |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Musculoskeletal chest pain                      |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Infections and infestations                     |                 |  |  |
| Urinary tract infection                         |                 |  |  |
| subjects affected / exposed                     | 2 / 26 (7.69%)  |  |  |
| occurrences (all)                               | 2               |  |  |
| Nasopharyngitis                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                               | 0               |  |  |
| Upper respiratory tract infection               |                 |  |  |

|                                    |                 |  |  |
|------------------------------------|-----------------|--|--|
| subjects affected / exposed        | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Sinusitis                          |                 |  |  |
| subjects affected / exposed        | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Bronchitis                         |                 |  |  |
| subjects affected / exposed        | 0 / 26 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Metabolism and nutrition disorders |                 |  |  |
| Decreased appetite                 |                 |  |  |
| subjects affected / exposed        | 6 / 26 (23.08%) |  |  |
| occurrences (all)                  | 6               |  |  |
| Dehydration                        |                 |  |  |
| subjects affected / exposed        | 2 / 26 (7.69%)  |  |  |
| occurrences (all)                  | 2               |  |  |
| Hyperglycaemia                     |                 |  |  |
| subjects affected / exposed        | 2 / 26 (7.69%)  |  |  |
| occurrences (all)                  | 2               |  |  |
| Hypokalaemia                       |                 |  |  |
| subjects affected / exposed        | 4 / 26 (15.38%) |  |  |
| occurrences (all)                  | 5               |  |  |
| Hypomagnesaemia                    |                 |  |  |
| subjects affected / exposed        | 2 / 26 (7.69%)  |  |  |
| occurrences (all)                  | 2               |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 03 May 2013       | Protocol amendment 01: Addition of defined clinical criteria for disease progression, clarification of definition of platinum sensitivity.                                                                                                                                                                                                                                                                              |
| 09 April 2014     | Protocol amendment 03: Clarified the following:<br>-assignment of participants to cohort based on Myriad Breast Cancer gene (BRCA) test,<br>-exclusion for immunocompromised participants,<br>-approach to dose modification and discontinuation due to hematologic events.<br>Added Cycle 1 visit for complete blood count (CBC) to allow early detection of hematologic abnormalities                                 |
| 04 December 2014  | Protocol amendment 04: Addition of centralized homologous recombination deficiency (HRD) testing and associated end points and sample size changes. Clarifying that dose modifications could be made at any time for intolerable toxicity                                                                                                                                                                               |
| 11 September 2015 | Protocol amendment 05: Clarification of exclusion criteria of corrected QT interval (QTc)-prolonging medications. Updated guidance on monitoring and following participants for potential risk for myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML).<br>Clarifying that progression is not considered an adverse event (AE).                                                                                |
| 09 March 2016     | Protocol amendment 06: Clarification of HRD+ definition and primary endpoint, addition of secondary objectives, and removal of an interim analysis.                                                                                                                                                                                                                                                                     |
| 31 May 2017       | Protocol amendment 07: Alignment with unblinding standard operating procedure (SOP) and updated standard niraparib safety language for AEs, serious AEs (SAEs), and adverse events of specific interests (AESIs) reporting.<br>Addition of primary analysis data to replace Phase 1 data.<br>Additional guidance for blood pressure monitoring.<br>Introduction of Extended Visit Cycle to minimize participant burden. |
| 29 January 2019   | Protocol amendment 08: Clarifying survival assessment and decreasing data collection burden in follow-up.<br>Alignment of safety language with updated niraparib risk management plan and General Data Protection Regulation                                                                                                                                                                                            |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported